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"Nearly all men die of their medicines, not of their diseases." 
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1 SUMMARY 
In this thesis the hepatotoxic properties of the two phytomedicines kava kava and cimicifuga 
racemosa have been investigated. This topic is a prevailing problem as herbal medicines are 
quite popular today and not much is known about their toxicological profile. Especially hepato-
toxicity is a wide-spread problem of medicines in general as most of them are metabolized in 
the liver and the liver therefore represents a near target. Ingestion of kava has been associated 
with liver damage and therefore Kava has been withdrawn from the market in different coun-
tries. For cimicifuga so far not much evidence for liver toxicity in humans exists. However, lately 
it was found that rats fed with high doses of cimicifuga developed microvesicular liver steatosis. 
In order to examine the in vitro toxicity of the two herbs the hepatocarcinoma cell line 
HepG2, the hepatoblastoma cell line HUH6, and isolated rat liver mitochondria have been 
used. Three kava extracts (a methanolic and an acetonic root extract; a methanolic leaf extract) 
and an ethanolic cimicifuga extract have been investigated. 
In the first project (chapter 6) toxicity of kava kava was investigated. It was found that all 
three kava extracts showed concentration-dependent toxicity in the general cytotoxicity tests. 
Experiments in mitochondria revealed that the kava extracts inhibited and uncoupled (root 
extracts) or only uncoupled (leaf extract) the respiratory chain and decreased the mitochondrial 
membrane potential; in addition, beta-oxidation was inhibited. Furthermore, oxidized gluta-
thione was slightly increased and ATP content of the cells was maintained. Apoptosis was 
found in HepG2 cells for all three kava extracts. These findings of mitochondria-related toxicity 
(affected respiratory chain, decreased mitochondrial membrane potential and increased 
reactive oxygen species (ROS) production) might result in the opening of the permeability 
transition pore and consequently in the rupture of the outer mitochondrial membrane, thus 
possibly leading to the release of cytochrome c and subsequently to apoptosis. These events 
might contribute to kava associated hepatotoxicity, especially in predisposed patients having 
mitochondrial damages. 
In the second project (chapter 7) two methods for cell death determination were applied 
and compared in the hepatoma cell lines HepG2 and HUH6 utilizing kava as death-inducing 
agent: the annexin V / propidium iodide (PI) stain and the green fluorescent protein (GFP)-
method. The annexin V / PI stain has already been established as a method to detect apoptosis 
and necrosis elicited by kava kava in the study mentioned above. The GFP-method had been 
described in different cell lines by other groups and is based upon the phenomenon that GFP 
decreases its fluorescence when apoptosis and/or necrosis occur. We found that the 
annexin V / PI stain and the GFP-method provided similar results. These results on the one 
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hand confirm that kava indeed induces cell death; on the other hand they show that the GFP-
method can also be employed in liver cell lines. Therefore, the GFP-method is suited as an 
easy, reliable, cost-effective method to screen substances for their hepatotoxic potential. 
In a further study (chapter 8) the toxicity profile of the phytomedicine cimicifuga was 
assessed. High doses of cimicifuga extract caused microvesicular liver steatosis in rats. Based 
on these findings in vitro experiments were performed to further investigate the hepatotoxic 
potential of this plant. General cytotoxicity tests revealed concentration-dependent toxicity. In 
mitochondria, cimicifuga extract was able to inhibit β-oxidation, to uncouple the respiratory 
chain and to reduce the mitochondrial membrane potential. In addition, HepG2 cells underwent 
apoptosis when incubated with cimicifuga. It might therefore be assumed that the impairment of 
the respiratory chain causes a decrease of the mitochondrial membrane potential, which in turn 
could lead to the opening of the permeability transition pore and to apoptosis. Whereas the 
inhibition of the β-oxidation may lead to accumulation of fatty acids and subsequently to liver 
steatosis. Toxicity was discovered at concentrations higher than the ones expected in humans. 
It is therefore conjectured, that hepatotoxicity in humans only occurs under certain conditions. 
Finally, it can be concluded that although kava kava and cimicifuga racemosa displayed 
clear toxicity in the in vitro situation it has to be further investigated whether these toxicities can 
be extrapolated to humans. Factors which have to be taken into account when estimating the 
toxic potential for humans include the concentrations used in the in vitro tests in comparison to 
portal venous concentrations in humans after intake of the extracts, the metabolism in the body, 
predisposing factors for liver toxicity like age, gender and pre-existing liver diseases, and poly-
medication. Nevertheless, these cytotoxicity tests represent a valuable tool for evaluating the 
toxic potential of herbal products before they reach the market. Of course, other experiments 
(animal experiments, for example) would have to be added, if an assessment corresponding to 
the rules of the regulatory offices is sought. These in-depth investigations are needed, if botani-
cals are to persist on the market in future. 
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2 ZUSAMMENFASSUNG 
In dieser Arbeit wurden die hepatotoxischen Eigenschaften der beiden Phytopharmaka Kava 
Kava und Cimicifuga racemosa untersucht. Dieses Thema ist ein aktuelles Problem, da pflanz-
liche Medikamente heutzutage sehr beliebt sind und nicht viel über ihr toxikologisches Profil 
bekannt ist. Vor allem Hepatotoxizität ist ein weit verbreitetes Problem bei Medikamenten im 
Allgemeinen, da die meisten über die Leber metabolisiert werden und die Leber deshalb einen 
nahe liegenden Angriffsort darstellt. Die Einnahme von Kava Kava wurde mit Leberschäden in 
Zusammenhang gebracht und deshalb wurde es in verschiedenen Ländern vom Markt ge-
nommen. Für Cimicifuga existieren bis jetzt kaum Hinweise auf Lebertoxizität beim Menschen. 
Es wurde jedoch kürzlich beobachtet, dass Ratten, die mit hohen Dosen Cimicifuga-Extrakt 
gefüttert wurden, eine mikrovesikuläre Lebersteatose entwickelten. 
Um die in vitro-Toxizität der zwei Pflanzen zu untersuchen, wurden die Hepatocarcinoma-
Zelllinie HepG2, die Hepatoblastoma-Zelllinie HUH6 und isolierte Rattenleber-Mitochondrien 
verwendet. Es wurden drei Kava-Extrakte – ein methanolischer und ein acetonischer Wurzel-
extrakt sowie ein methanolischer Blattextrakt – und ein ethanolischer Cimicifuga-Extrakt 
untersucht. 
Im ersten Projekt (Kapitel 6) wurde die Toxizität von Kava Kava untersucht. Dabei wurde 
gefunden, dass alle drei Kava-Extrakte konzentrationsabhängige Toxizität in den allgemeinen 
Toxizitätstests zeigten. Experimente in Mitochondrien enthüllten, dass die Kava-Extrakte die 
Atmungskette inhibieren und entkoppeln (Wurzelextrakte) oder nur entkoppeln (Blattextrakt); 
ausserdem war die β-Oxidation gehemmt. Des Weiteren war das oxidierte Glutathion leicht 
erhöht und der ATP-Gehalt der Zellen blieb aufrechterhalten. In HepG2 wurde für alle drei 
Kava-Extrakte Apoptose gefunden. Diese Ergebnisse mitochondrieller Toxizität (beeinträchtigte 
Atmungskette, erniedrigtes Mitochondrien-Membranpotential und erhöhte ROS-Produktion) 
könnten zur Öffnung der Permeabilitäts-Transitions-Pore und infolgedessen zum Aufreissen 
der äusseren Mitochondrienmembran führen, was möglicherweise die Freisetzung von Cyto-
chrom c und daraus folgend Apoptose verursacht. Diese Ereignisse könnten zur Kava-
assoziierten Hepatotoxizität beitragen, vor allem bei prädisponierten Patienten mit 
mitochondriellen Schäden. 
Im zweiten Projekt (Kapitel 7) wurden zwei Methoden zur Zelltod-Bestimmung in den 
Hepatoma-Zelllinien HepG2 und HUH6 mit Kava-Extrakt als Zelltod-auslösendem Agens 
angewendet und verglichen: die Annexin V / Propidiumiodid (PI)-Färbung und die GFP-
Methode. Die Annexin V / PI-Färbung wurde schon in der oben erwähnten Arbeit zur Detektion 
von Kava-verursachter Apoptose und Nekrose etabliert. Die GFP-Methode wurde durch andere 
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Gruppen in verschiedenen Zelllinien beschrieben und basiert auf dem Phänomen, dass sich die 
GFP-Fluoreszenz reduziert, wenn Apoptose und/oder Nekrose auftreten. Wir haben gefunden, 
dass die Annexin V / PI-Färbung und die GFP-Methode ähnliche Resultate lieferten. Diese 
Resultate bestätigten auf der einen Seite, dass Kava tatsächlich Zelltod induziert. Andererseits 
zeigten sie, dass die GFP-Methode auch in Leber-Zelllinien angewendet werden kann. Aus 
diesem Grund kann die GFP-Methode als eine einfache, Kosten sparende, verlässliche 
Methode für das Screenen von Substanzen bezüglich ihres hepatotoxischen Potentials 
verwendet werden. 
In einer weiteren Studie (Kapitel 8) wurde das Toxizitätsprofil des Phytopharmakons 
Cimicifuga racemosa abgeschätzt. Hohe Dosen von Cimicifuga verursachten mikrovesikuläre 
Steatose in Ratten. Basierend auf diesen Ergebnissen wurden in vitro-Experimente durch-
geführt um das hepatotoxische Potential dieser Pflanze weiter zu untersuchen. Allgemeine 
Zytotoxizitätstests zeigten konzentrations-abhängige Toxizität. In Mitochondrien vermochte der 
Cimicifuga-Extrakt die β-Oxidation zu hemmen, die Atmungskette zu entkoppeln und das 
mitochondrielle Membranpotential zu reduzieren. Ausserdem wurde in HepG2-Zellen Apoptose 
induziert. Es könnte deshalb angenommen werden, dass die Beeinträchtigung der Atmungs-
kette eine Erniedrigung des mitochondriellen Membranpotentials verursacht, was zur Öffnung 
der Permeabilitäts-Transitions-Pore und daraus folgend zu Apoptose führen könnte. 
Dahingegen könnte die Hemmung der β-Oxidation zur Akkumulation von Fettsäuren und an-
schliessend zu Lebersteatose führen. Die gefundene Toxizität trat bei höheren Konzentrationen 
auf als bei denen, die im Menschen erwartet würden. Es wird deshalb spekuliert, dass nur 
unter bestimmten Voraussetzungen Hepatotoxizität im Menschen auftritt. 
Obwohl Kava Kava und Cimicifuga racemosa eine deutliche Toxizität in der in vitro-
Situation zeigten, kann abschliessend gefolgert werden, dass weiter untersucht werden muss, 
ob diese Toxizitäten auf den Menschen übertragen werden können. Faktoren, die beachtet 
werden müssen, wenn das toxische Potential für den Menschen abgeschätzt werden soll, sind 
die in den in vitro-Tests verwendeten Konzentrationen im Vergleich zu Portalvenenkonzentra-
tionen im Menschen nach Einnahme der Extrakte, der Metabolismus im Körper, prädisponie-
rende Faktoren für Lebertoxizität wie Alter, Geschlecht und vorbestehende Lebererkrankungen 
und Polymedikation. Dennoch stellen diese Zelltoxizitätstests ein wertvolles Hilfsmittel für die 
Evaluation des Toxizitätspotentials pflanzlicher Produkte dar, bevor sie auf den Markt kommen. 
Natürlich müssten noch weitere Experimente, wie z. B. Tierexperimente, beigefügt werden, 
wenn eine Beurteilung gemäss den Regeln der Zulassungsbehörden angestrebt wird. Diese 
vertieften Untersuchungen sind nötig, wenn Phytopharmaka auch in Zukunft auf dem Markt 
bestehen sollen. 
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3 ABBREVIATIONS 
293T human embryonal kidney cell line 
ADP adenosine diphosphate 
AIF apoptosis inducing factor 
Apaf-1 apoptotic protease activating factor 1 
AR acetonic root extract 
ATP adenosine triphosphate 
BPDS bathophenanthrolinedisulfonic acid 
BSA bovine serum albumin 
Cy3 a fluorescent cyanine dye 
CYP cytochrome P450 enzymes 
DHK dihydrokavain 
DHM dihydromethysticin 
Diablo = Smac 
DISC death-inducing signaling complex 
DMSO dimethyl sulfoxide 
DMY demethoxyyangonin 
DNP 2',4'-dinitrophenol 
DTNB 5,5'-dithiobis(2-nitrobenzoic acid) 
EDTA ethylenediaminetetraacetic acid 
EGFP enhanced green fluorescent protein 
ER endoplasmic reticulum 
FACS fluorescence activated cell scanning 
FADD Fas associated death domain 
FADH flavin adenine dinucleotide 
Fas Fas-receptor (= CD95) 
FasL soluble Fas ligand cellular supernatant 
FSC forward scatter 
GFP green fluorescent protein 
GSH reduced glutathione 
GSSG oxidized glutathione 
H2O2 hydrogen peroxide 
HEPES N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) 
HepG2 human hepatocarcarcinoma cell line 
HRT hormone replacement therapy 
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HtrA2 high temperature requirement protein A2 = OMI 
HUH6 human hepatoblastoma cell line 
IAP inhibitor of apoptosis proteins 
IgG immunglobuline G 
JC-1 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-benzimidazolylcarbocyanine iodide 
K kavain 
LDH lactate dehydrogenase 
M methysticin 
ML methanolic leaf extract 
MPT mitochondrial permeability transition 
MR methanolic root extract 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NADH nicotinamide adenine dinucleotide 
NADPH nicotinamide adenine dinucleotide phosphate 
OMI = HtrA2 
PBS phosphate buffered saline pH 7.4 
PCA perchloric acid 
Pefa Pefablock 
PI propidium iodide 
RCR respiratory control ratio 
ROS reactive oxygen species 
RPMI Roswell Park Memorial Institute 1640 medium 
SE standard error of the mean 
Smac second mitochondria-derived activator of caspase = Diablo 
SRB sulforhodamine B 
SSC side scatter 
TNB 5-thio-2-nitrobenzoic acid 
TNF tumor necrosis factor 
TRAIL tumor necrosis factor (TNF)-related apoptosis-inducing ligand 
Y yangonin 
zFA-fmk Z-Phe-Ala-fluormethylketone 
zVAD-fmk Z-Val-Ala-Asp-fluoromethylketone 
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4 INTRODUCTION 
The use of plants as medicines has a very long tradition. Already the earliest humans availed 
themselves of herbs for the treatment of manifold ailments and diseases. On the other hand, 
people were also aware of their negative sides and used them as poisons. Over the course of 
the centuries new substances in the field of chemistry and pharmacology were discovered and 
people enforced the advancement of these findings. Especially in the 20th century a great leap 
in the discovery of chemical agents was made and the herbal knowledge and medicines fell 
into oblivion, particularly in the Western countries. Only in the 80ties and 90ties of the 20th 
century, as people were increasingly tired of the chemical drugs with their side effects etc., 
more and more people remembered the old herbal remedies and fell back on these traditional 
medicines. Phytopharmaceuticals became popular all around the world. In the course of this 
development studies examining the efficacy of these herbal medicines were undertaken – but 
the safety aspect has been neglected to a great deal. Only as cases of toxicity emerged in man 
attention was paid to this aspect. 
The aim of this work was to shed light on the toxicity potential and mechanisms of kava 
kava and cimicifuga racemosa extracts, representing two examples of herbal remedies where 
toxicity has not been elucidated yet. 
The following chapters are meant to give a short introduction into the field of toxicology, 
with emphasis to toxicity mechanisms, liver toxicity and toxicity of phytomedicines. 
 
4.1 Toxicology 
Toxicology is a young science that developed only during the last 40 years as concern for 
consumer and worker health and for the environment increased. Currently, toxicology encom-
passes mainly activities to determine the potential for adverse effects from chemicals (both 
natural and synthetic), with the objective of assessing hazard and risk to humans and animals. 
Based on this appropriate precautionary, protective, restrictive and therapeutic measures can 
be defined [1]. 
In toxicology the emphasis has changed from acute, particularly human, toxicology to long-
term and non-target species toxicology. The following two key issues are embedded in the term 
toxicology: First, a close structural or functional contact of chemicals, or their conversion 
products, to tissues or organs and second a quantitative relationship between the triggering 
agent and the effect. Such a dose-response relationship is important for a causality assess-
ment and to predict the dimension of risk and hazard. 
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The term "toxicity" is used to describe the nature of adverse effects produced and the con-
ditions required for their induction; i.e. toxicity is the potential for a material to cause harm in 
biological systems [1]. For pharmacologically active and therapeutic agents undesired effects 
are described by different terms: side-effects, overdosage, underdosage, loss of effect, intole-
rance, idiosyncrasy, secondary effects, and adverse drug interactions. 
The nature and magnitude of a toxic effect of a compound depend on several factors like 
its physicochemical properties, its pharmacokinetic behavior, the conditions of exposure and 
the presence of bioprotective mechanisms. Examples for the expression of a toxic response 
are inflammation, necrosis, apoptosis, enzyme inhibition, biochemical uncoupling, lethal 
synthesis, lipid peroxidation, covalent binding, receptor interaction, immunosuppression or 
neoplasmia [1]. 
 
4.2 Mechanisms of Toxicity 
4.2.1 Apoptosis and Necrosis 
Cell proliferation and cell demise are processes which are tightly regulated in normal function-
ing cells and tissues. The balance between dying and growing is sustained by various mecha-
nisms. A disequilibrium of this system would lead to different detrimental outcomes. On the one 
hand, when cell death is preponderant, cell loss is high, for example in conditions like reperfu-
sion injury, heart failure, AIDS, neurodegeneration, ostheoarthritis. On the other hand, when 
cell death is hindered, i.e. cells can proliferate uncontrolled, dangerous conditions like cancer, 
viral infections, restenosis, autoimmunity occur [2, 3]. From this follows that cell death and its 
regulation has an important role in all creatures. 
In physiological conditions, cell death is mediated by a process called apoptosis and is a 
strictly regulated course of events removing superfluous, aged, or damaged cells. In this con-
text, mitosis can be regarded as the opposite process in the regulation of the cell population. 
Apoptosis is derived from the ancient Greek and means "the falling of petals from a flower" or 
"of leaves from a tree in the autumn" [4]. The term apoptosis was first used by John Kerr in 
1972 [5], although this morphological phenomenon has been described already more than 
hundred years earlier by Carl Vogt in 1842 [4]. However, cells can not only die from apoptosis, 
but also from another kind of cell death termed necrosis. Necrosis is always induced after 
exposure to (high doses of) external factors or drastic changes in the physiological environ-
ment, such as heat, anoxia, loss or increase of ions, ethanol, toxic substances and usually is a 
pathogenic process [6]. Also apoptosis can be triggered not only by growth regulation of tissues 
but also by external factors, which can be the same as the ones causing necrosis. In general, 
the trigger needs to be more massive to provoke necrosis instead of apoptosis. Apoptosis and 
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necrosis not only differ in the triggers and the course of events, but also in the picture they 
present during this process. 
The image of apoptosis is characterized by the shrinkage of the cell and the cell nucleus, 
condensation of chromatin, DNA fragmentation, and blebbing of the cell membrane with the 
constriction of apoptotic bodies without loosing the structural integrity and most of the plasma 
membrane function [6, 7]. Whereas necrosis is represented by swelling of the cell and the cyto-
plasmatic organelles and disrupture of the cell membrane leading to inflammation and thus 
causing further tissue damage (Figure 1) [6]. In apoptosis, inflammation is usually prevented by 
the engulfment and lysis of apoptotic bodies by phagocytes, which in addition results in the 
release of anti-inflammatory cytokines and immune tolerance [8]. Also scar formation usually 
does not take place. However, if apoptosis is massive or phagocytic cells are lacking, apoptosis 
can eventually turn into necrosis [9]. 
 
 
Figure 1: Scheme illustrating morphological and biochemical changes during apoptosis and necrosis [7]. 
 
Apoptosis can be triggered mainly by two pathways [4, 10, 11]: the intrinsic and the extrinsic 
pathway. The intrinsic pathway is starting from the mitochondria as consequence of extra- or 
intracellular stress, the other is triggered by an extracellular ligand activating a death receptor in 
the cell membrane (Figure 2). In both pathways so-called caspases are usually involved. Cas-
pases are cysteine containing aspartic acid-specific proteases and can be divided into initiator 
caspases (caspases 8, 9 and 10) and downstream or executioner caspases (caspases 3, 6, 7,) 
[4, 12]. Upon activation of a death receptor (Fas-, TRAIL- or TNF-receptor) recruiting of adaptor 
molecules (such as FADD: Fas associated death domain proteins) and procaspases occurs, 
forming an "apoptosome", a so-called DISC (death-inducing signaling complex).  
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Figure 2: The death-receptor pathway (left pathway) is triggered by members of the death-receptor superfamily 
(such as CD95 (= Fas) and tumour necrosis factor receptor I). The mitochondrial pathway (right) is used 
extensively in response to extracellular cues and internal insults such as DNA damage. These diverse 
response pathways converge on mitochondria, often through the activation of a pro-apoptotic member of 
the Bcl-2 family. In addition, pro- and anti-apoptotic Bcl-2 family members meet at the surface of mito-
chondria, where they compete to regulate cytochrome c exit. If the pro-apoptotic camp wins, an array of 
molecules is released from the mitochondrial compartment. The death-receptor and mitochondrial path-
ways also converge at the level of caspase-3 activation. Caspase-3 activation and activity is antagonized 
by the IAP proteins, which themselves are antagonized by the Smac/DIABLO protein released from mito-
chondria [13]. 
 
In this complex procaspases are transactivated and subsequently cleaved, resulting in active 
caspases, which activate downstream caspases [10]. These effector caspases then cleave 
cellular substrates leading to the phenomena of the apoptotic picture. The intrinsic pathway is 
initiated by some kind of stress, like oxidative stress or treatment with cytotoxic drugs, and 
starts with the release of cytochrome c from the mitochondrial intermembrane space into the 
cytosol. Cytochrome c aggregates with apoptotic protease activating factor 1 (Apaf-1), procas-
pase-9 and ATP to form an apoptosome [14]. Upon procaspase-9 activation an effector 
caspase, e.g. caspase-3, is activated. The latter can trigger the evolvement of the apoptotic 
morphology, like in the extrinsic pathway. Apoptosis, and especially caspase activation, is an 
energy-requiring process. In case ATP is decreased apoptosis is blocked and turns into 
necrosis [15, 16]. 
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In reality, the whole situation is much more complex. The two pathways are not only con-
nected by the convergence at the level of the executioner caspases but can also be at an 
earlier stage. The activated initiator caspase-8 not only cleaves and activates caspase-3 but 
also Bid, a proapoptotic member of the Bcl-2 family. Bid acts on mitochondria to trigger the 
release of cytochrome c with the above described consequences. Under most conditions, this 
cross-talk is minimal, and the two pathways operate largely independently of each other. During 
the whole process of apoptosis also further pro- and anti-apoptotic molecules are involved 
which regulate the death process at several places (see Figure 2) [10, 11, 13]. 
The whole course of events can be expressed as a three-step model of apoptosis: a pre-
mitochondrial phase during which signal transduction cascades and damage pathways are 
activated; a mitochondrial phase during which mitochondrial membrane function is lost; and a 
post-mitochondrial phase during which proteins released from mitochondria elicit the activation 
of catabolic proteases and nucleases [17]. However, also caspase-independent death pro-
cesses exist, in which no caspases but other proteases, including cathepsins, calpains and 
endonucleases, are activated [18]. 
 
4.2.2 Mitochondria 
Mitochondria are key players in the functioning of a cell as their primary role is providing cells 
with energy in form of ATP, which is produced by the coupling of the ATP synthase with the 
electron transport chain. The respiratory chain is fed with reductive equivalents (NADH and 
FADH2) from the citric acid cycle, β-oxidation, and glycolysis. Mitochondria encompass the 
important metabolic pathways of tricarboxylic acid cycle and fatty acid β-oxidation. In addition, 
they have a central role in ion homeostasis and redox regulation [19]. 
It is assumed that mitochondria originally evolved from aerobic prokaryotic bacteria who 
underwent symbiosis with anaerobic host cells. This co-living represented a benefit for both 
parties as their survival was increased due to the better exploitation of energy in foodstuff [20]. 
Mitochondria consist of two compartments, the matrix, circumvented by the inner membrane, 
and the intermembrane space, which is delineated by the outer membrane. The inner mem-
brane is folded forming so-called cristae, which clearly enlarge the surface, and is hardly 
permeable under physiological conditions. This tightness ensures the maintenance of the elec-
trochemical gradient, comprising a membrane potential (negative inside) and a pH gradient 
(basic inside), which is the basis of the coupling of the respiratory chain to oxidative phospho-
rylation. The protein complexes of the respiratory chain are embedded in the inner membrane. 
The outer membrane is much more permeable for low-molecular-weight solutes. Mitochondria 
consume more than 90 % of the cells oxygen and supply most of our ATP [21, 22]. Most cells 
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contain hundreds of mitochondria [23]. Organs with high energetic requirements contain more 
mitochondria to cope with this situation, e.g. heart, muscle. 
A drawback of the production of ATP is the generation of reactive oxygen species (ROS) 
by the respiratory chain, which is especially pronounced at complexes I and III [24]. Mitochon-
dria are the major source of ROS and as mentioned above play also a pivotal role in apoptosis. 
They are the central element in the intrinsic apoptosis pathway. Upon the impact of a trigger 
they release several molecules from the intermembrane space, which initiate the apoptotic 
answer including Apaf-1, cytochrome c, apoptosis inducing factor (AIF) (see chapter 4.2.1). 
Concomitantly, an opening of the mitochondrial permeability transition (MPT) pore and a 
dissipation of the mitochondrial membrane potential occurs, both of them early signs of cell 
death. Mitochondrial apoptogenetic factors can be divided into two groups: the caspase-
dependent substances and the caspase-independent factors (e.g. AIF, high temperature 
requirement protein A2 (HtrA2/OMI) and endonuclease G) [25]. Summarized it can be stated 
that mitochondria are able to trigger both caspase-dependent and caspase-independent apop-
totic cell death. 
Induction of the MPT is sufficient to trigger apoptosis or necrosis and the pharmacological 
inhibition of MPT prevents cell death [26]. As a consequence of MPT pore opening, solutes 
< 1500 Da diffuse across the inner mitochondrial membrane, causing mitochondrial depolari-
zation, uncoupling of oxidative phosphorylation, and large amplitude swelling, which in turn can 
lead to depletion of ATP and cell death [16]. MPT can be favored by high calcium concentration 
in the mitochondrial matrix, NAD(P)H oxidation and mitochondrial generation of ROS, whereas 
magnesium, low pH and cyclosporine A inhibit MPT (Figure 3) [15]. 
 
 
Figure 3: Mitochondrial involvement in cell death, with focus on events proximal to the regulation of mitochondrial 
membrane permeabilization (MMP = MPT). Mitochondrial membrane effectors may cause MMP, 
depending on local regulators which sensitize mitochondria to MMP or inhibit MMP. Permeabilization of 
the outer and/or inner mitochondrial membranes then triggers a series of catabolic reactions that entail 
cell death, either by apoptosis or by necrosis [27]. 
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Massive induction of MPT leads, via depletion of ATP, to necrosis, whereas a more subtle, 
regulated induction of MPT gives time for the activation and action of proteases ending in 
apoptosis [6]. As possibility, one could imagine that the respective outcome of the bioenergetic 
and redox "catastrophe" on one side and the activation of catabolic enzymes (caspases and 
nucleases) on the other side might compete in some sort of race. This could explain, why some 
substances induce apoptosis as well as necrosis, depending on the applied concentration. In 
this context, a new term can be introduced: necrapoptosis. Necrapoptosis describes death pro-
cesses which begin with a common stress or death stimulus, share the same pathways, but 
finally lead to either necrosis or apoptosis, depending on modifying factors like ATP (Figure 4) 
[15, 16]. Formigli described the same phenomenon as aponecrosis [28]. 
Once cytochrome c is released and mitochondrial membrane potential is disrupted, the cell 
is committed to die either by apoptosis – through Apaf-1 mediated activation of caspases – or 
by necrosis – as a result of the collapse of the respiratory function due to increased ROS and 
insufficient supply of ATP [20, 29-31]. 
 
 
Figure 4: Scheme showing the role of ATP in necrapoptosis mediated by the mitochondrial permeability transition. 
When the MPT occurs abruptly, activation of mitochondrial ATPases causes ATP depletion, which leads 
to plasma membrane rupture and necrotic cell death. In case MPT progresses relatively slowly ATP levels 
remain relatively preserved even after onset of the MPT. Under such conditions, cytochrome c release 
activates a cascade of caspases, endonucleases, and other degradative enzymes, causing apoptotic 
rather than necrotic cell death. At any time, ATP depletion can supervene to cause secondary necrosis 
[15]. 
 
When cells are exposed to environmental stress cell cycle is arrested at G0 or G1 phase and 
mitochondria are motivated to produce more ATP in order to provide more energy for repairing 
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the damage sustained. Signals, like H2O2, are sent to the nucleus to initiate proliferation of 
mitochondria and concomitantly mitochondrial DNA (mtDNA) amplification in order to allocate 
more mitochondria to fulfill this task [20]. 
The mtDNA is more susceptible to mutations than nuclear DNA, e.g. caused by ROS, as it 
is a naked compact DNA molecule without protective histones, is rapidly and frequently repli-
cated without proofreading or efficient DNA repair systems and is located near the major ROS 
source [19, 20, 32]. This leads to an increased percentage of damaged mtDNA (somatic muta-
tions) with increasing age, possibly associated with decreased mitochondrial function and 
enhanced ROS production (Figure 5) [19]. The resultant age-related decline in oxidative 
phosphorylation would lead to a reduction of bioenergetic capacity until a certain threshold is 
undershot and symptoms or senescence occur [23]. 
 
 
Figure 5: Mitochondrial role in the determination of life and death of the cell. Under normal physiological conditions, 
mitochondria are the major source of bioenergy and ROS. To cope with the ROS, human cells have 
developed an efficient scavenger system, which includes antioxidant enzymes and small molecular-weight 
antioxidants (left panel). Although this system can dispose of ROS and free radicals, a small proportion of 
them may escape these defense mechanisms and cause damage to cellular constituents including DNA, 
RNA, proteins, and lipids. The ratio of damaged or mutated mtDNA to wild-type mtDNA can result in bio-
energetic and/or redox alteration of tissue cells. Therefore, in a synergistic manner, all mutations and 
oxidative damage to mtDNA cause a deleterious effect on the respiratory function of mitochondria and 
lead the affected individual to aging and degenerative disorders (right upper panel). On the other hand, 
mitochondria can sense and respond to extracellular and intracellular signals and stresses. Once beyond 
a threshold of stress or challenge (e.g., ROS-elicited oxidative stress), mitochondria may drive the cell into 
an irreversible cell death process (right lower panel) [20]. 
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4.2.3 Reactive oxygen species 
Another important factor influencing cell functioning is the occurrence of reactive oxygen 
species. Cells are constantly generating ROS during aerobic metabolism. ROS is an umbrella 
term for several reactive molecules containing oxygen, including O2˙¯ (superoxide anion), ˙OH 
(hydroxyl radical), and H2O2 (hydrogen peroxide). They origin mainly from the mitochondrial 
respiratory chain, where about 1 – 5 % of the electrons lose their way and directly interact with 
oxygen to form O2˙¯ [31]. Other sources are the microsomal electron transport chain or oxida-
tive enzyme systems like xanthine oxidase, cyclooxygenase, lipoxygenase, cytochrome P450, 
and NADPH oxidase [33]. 
Most of the produced ROS are caught by the endogenous antioxidant system. This system 
consists of enzymes like catalase, superoxide dismutase, glutathione peroxidase, and the 
molecule glutathione. Glutathione is a tripeptide (γ-Glu-Cys-Gly) occurring in two forms in the 
cell: reduced (GSH) and oxidized (GSSG) glutathione, with GSH being the predominant form. 
Depletion of GSH is sufficient to trigger apoptosis in some cell types and is able to make cells 
more susceptible to other apoptosis inducing stimuli [34, 35]. 
Oxidative stress is induced if the natural antioxidant defense cannot cope anymore with the 
incidental ROS. The effects that ROS may have on the cell are manifold. First of all, ROS are 
able to oxidize DNA with subsequent wrong or hampered synthesis of proteins leading to mal-
functioning and structural changes of these proteins (see chapter 4.2.2). Moreover, they may 
also peroxidize membrane lipids causing dysfunction of the cell membrane. By modifying the 
DNA bases they are able to impair the DNA repairing mechanisms and through hydrolysis they 
lead to malondialdehyde production from deoxyribose [33]. 
Oxidative stress is involved in the pathogenesis of several diseases including AIDS, 
Huntington's, Parkinson's disease, Alzheimer's disease, sepsis, artherosclerosis, and retinal 
degenerative disorders [36]. 
 
4.3 Drug-induced liver toxicity 
Liver toxicity is a very common adverse event of a drug. More than 1100 drugs world-wide are 
thought to be potentially hepatotoxic [37]. Drug-induced liver injury is the most frequent cause 
for the after-marketing withdrawal of a drug, despite rigorous preclinical and clinical testing [38]. 
There are three reasons for this high frequency: better diagnostic possibilities, a growing 
number of potentially hepatotoxic medicaments coming to the market, and the liver's central 
role in the metabolism and disposition of drugs [39]. 
The clinical picture of liver toxicity corresponds to the common liver diseases and can vary 
from reversible, mild liver enzyme elevation to fatal liver failure, including necrosis, hepatitis, 
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cholestasis, steatosis, veno-occlusive disease, cholangitis, cirrhosis, hepatocellular carcinoma, 
with acute hepatitis being the most frequent presentation (90 % of cases). Several risk factors 
are known for the development of hepatotoxicity of drugs, like gender, age, lack of food, adipo-
sitas, diabetes mellitus, liver diseases, renal diseases, heart diseases, hyperthyreosis, psoria-
sis, rheumatic diseases, AIDS, pregnancy, long-term therapies, dosage, polymedication, 
alcohol abuse, genetic factors, and others. The underlying causes can be of allergic-immuno-
logic or metabolic-toxic nature, but the hepatotoxicity mechanisms of most drugs remain 
unknown [40, 41]. Formation of reactive metabolites is relatively frequent. Despite several 
protective mechanisms, this may lead to the covalent binding of electrophilic metabolites to 
proteins, the mutation of lipid peroxidation by free radicals, and the depletion and/or oxidation 
of glutathione. A number of structural and functional lesions, including a sustained release in 
cytosolic calcium, eventually leading to cell death, follow the before mentioned events [41]. 
Immunologic responses are rare (often less than 1 case per 1000 treated patients), unex-
pected, delayed (from 2 weeks to several month), host-dependent and not dose-related 
reactions, which can be persistent; autoantibodies or antibodies against modified proteins in the 
blood of patients frequently occur. As mechanism for this immunoallergic hepatitis has been 
postulated that the respective drug is enzymatically converted to a reactive metabolite, which 
binds to the enzyme that produced it. This complex is called neoantigen, which once presented 
to the immune system, causes an immune response by the production of antibodies against 
both the natural protein and/or the modified protein. Examples of drugs causing an 
immunoreaction in the liver are halothane, tienilic acid, anticonvulsants [38, 39, 42, 43]. 
Causes for the development of hepatotoxicity of metabolic-toxic origin consist of the 
following mechanisms: metabolite-mediated toxicity and endothelial lesions, inhibition of biliary 
secretion, decreased secretion of lipoproteins, inhibition of fatty acid mitochondrial β-oxidation, 
or activation of Ito cells [41]. Activation of Kupffer cells leads to the release of cytotoxic media-
tors, such as reactive oxygen species, and proinflammatory mediators, such as cytokines and 
chemokines [44]. 
Directing damaged cells to apoptosis, rather than necrosis, might be very beneficial as by 
this way consequential reactions like inflammation can be prevented, provided cell death is not 
massive. On the other hand interfering with the apoptosis program risks to direct cells to necro-
sis with secondary consequences which can further aggravate the injury [45]. 
 
4.4 Toxicity of Phytomedicines 
At all times, people tried to treat and cure themselves with some kind of medicine. Originally, 
treatment occurred with natural substances, lately moving to industrially synthesized drugs. 
Nowadays, phytomedicines enjoy great popularity again. The reasons for this attractiveness 
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are the perceiving that natural medicines are safe, gentle and cost-effective, the easy accessi-
bility, and the desire of self-medication [46]. Out of this, people often use herbal drugs as self-
medication, i.e. without the doctor's knowing. The problem is that people take them not only as 
exclusive medication but also in combination with other – practitioner-prescribed – drugs. 
Especially in the USA, where herbal medicines are categorized as dietary supplements and 
therefore are available in the supermarket, the dispensing and sales and distribution is inade-
quately controlled and their regulatory requirements do not correspond to the standards of 
conventional drugs, i.e. the efficacy, quality control and safety of a product [47]. In other coun-
tries like Germany a series of herb recommendations, the Commission E Monographs, had 
been implemented, detailing dosages and indications of herbs whose efficacy is supported by 
the literature. 
There are several typical problems in connection with botanicals: contamination (e.g. 
heavy metals), adulteration, interaction with other drugs (e.g. Hypericum perforatum), and toxi-
city itself (e.g. kava kava) [48]. Contaminations can occur unintentionally as well as delibe-
rately, whereas adulterations are committed fraudulently. Clinical relevant adulterants and 
contaminants consist of toxic botanicals and botanical substances, pathogenic microorganisms 
and microbial toxins, pesticides and fumigation agents, toxic metals, and pharmaceuticals [49]. 
Examples for adulterants found in traditional Chinese medicines are acetaminophen, cortico-
steroids, caffeine, diazepam, diclofenac, hydrochlorothiazide, fluocinoline, glibenclamide, 
mefenamic acid, and phenytoin [50]. 
Recently, efforts have been undertaken to study the efficacy and mechanism of action of 
botanicals, but the safety aspect has been neglected to a high degree. Especially, about the 
way by which toxicity is elicited only few is known and investigated so far. Often, cases of toxi-
city caused by a botanical are becoming known through single case reports and not based on 
clinical trials. Therefore, adverse reactions to herbals are probably underrecognized and 
underreported [51]. Herbal preparations contain quite an amount of pharmaceutically active 
ingredients, which potentially could all produce negative effects and make it not easy to 
denominate the actually side effect-causing constituent. Increasingly, it seems that the health 
hazards outnumber the beneficial effects of herbal medicinals [52]. Most herbs share the 
pharmacological mechanisms of action with already existing prescription or over-the-counter 
drugs [47], potentially leading to some kind of interaction. 
Phytomedicinals can evoke a big variety of physical detrimental effects. An overview of 
these effects is given in Table 1, which is adopted from Winslow and Kroll, and a summary of 
adverse events of the 20 best-selling herbs in the USA is provided by De Smet [49]. Herbs can 
effect quasi every organ or function in the body. In the following, emphasis is placed on liver 
toxicity of herbal medicinals. For establishing an accurate diagnosis of hepatotoxicity, several 
aspects should be considered including thorough anamnesis, pattern recognition, awareness of 
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the spectrum of herbal liver injury and botanic identification [53]. Before a liver disease can be 
associated with a phytomedicine, other causes, like hepatitis viruses and autoimmune disor-
ders, should be excluded. In cases of botanical-induced liver toxicity, the clinical picture is 
usually not different from other forms of liver diseases, thus encompassing a wide spectrum of 
liver pathology including elevated liver enzymes, hepatitis, fibrosis, cirrhosis, and acute liver 
failure [53] (see also chapter 4.3). Examples of herbal medicines suspected to cause liver injury 
are chaparral (Larrea tridentata), Dai-saiko-to (Sho-saiko-to, TJ-9), greater celandine, Ma-
huang (from Ephedra species), pennyroyal oil, saw palmetto (Serenoa repens), germander 
(Teucrium chamaedris), valerian, mistletoe [52-54]. Pyrrolizidine alkaloids, contained in plants 
like Heliotropium, Senecio, Symphytum (Compositae), are able to induce veno-occlusive 
disease. 
In some cases, (hepato)toxic effects do not originate from sole intake of botanicals but 
from the combination with other drugs. These interactions can occur via the induction of CYPs 
(like CYP3A4 or CYP2E1) by other drugs or alcohol, which may enhance the production of 
toxic herbal metabolites [54]. On the other hand, herbal components may act on CYPs by 
inhibiting these, thus potentially leading to accumulation of concomitantly taken drugs. In an in 
vitro study, inhibition of CYP 2C9, 2C19 and 3A4 by kava kava, Ginkgo biloba, garlic, and 
St. John's wort was found [55]. But interactions may not only occur via CYPs, but also by other 
pathways, including the immune system (Echinacea – corticosteroids, cyclosporine), the clot-
ting system (garlic, ginger, ginkgo – warfarin), the cardiac system (herbs containing cardiac 
glycosides – digoxin), and the renal system (licorice – spironolactone) [56]. 
In this work, two herbs will be investigated regarding their hepatotoxic potential: kava kava 
and cimicifuga racemosa. Details concerning these plants will be discussed in chapter 6 and 
chapter 8 later in this thesis, however a short introduction will be given at this place. 
Kava kava is a shrub originating from Oceania. It became popular some years ago as 
herbal alternative to the classically used benzodiazepines as anxiolytic and mild sedative. A 
few years ago, kava has been withdrawn form the market in many countries because of its 
association with liver toxicity. First, only acetonic extracts have been taken from the market, but 
later all products have been banned. 
Cimicifuga racemosa is a herb native to the Eastern United States and Canada. It is now 
widely used as herbal alternative to the standard hormone replacement therapy (HRT) in the 
treatment of menopausal complaints. As HRT was linked to breast cancer as well as cardio-
vascular disease and many women asked for more natural medication cimicifuga gained great 
popularity in the last years. However, so far not much is known about the hepatotoxic potential 
of cimicifuga and as it is a widely used phytomedicine it would be interesting to learn more 
about its toxicological profile. 
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Table 1: Reported adverse effects of some common herbs [47] 
Organ System Toxic Effects Herb Comments 
Gastrointestinal Hepatotoxic (from asympto-
matic enzyme elevation to 
fulminant necrosis) 
Nausea/vomiting 
 
Diarrhea 
Chinese herbal teas, mistletoe, 
germander, chaparral, or com-
frey 
Dandelion, garlic, ginseng, or 
chaparral 
Herbal teas, aloe, ligustrum, 
dandelion, prunella, garlic, or 
ginseng 
First reported case of hepatic 
veno-occlusive disease was 
caused by comfrey 
Hematologic Anticoagulant/antiplatelet Yarrrow, red clover, tang-kuei, 
pau d'arco, or salvia 
 
Central nervous system Nervousness, agitation, insom-
nia, mood changes, depres-
sion, confusion, or halluci-
nations 
Cholinergic toxicity 
 
 
Hallucinogenic 
 
 
 
Sedation 
Seizures, psychosis, or coma 
Ginseng 
 
 
 
Jimson weed 
 
 
Catnip, hops, kava kava, khat, 
lobelia, mandrake, nutmeg, 
jimson weed, valerian, or 
yohimbe 
Peony, salvia, or tang-kuei 
Ephedra 
With long-term use and higher 
doses 
 
 
Contains atropine, scopo-
lamine, hyoscyamine 
Pulmonary Pulmonary hypertension Chinese herbal teas  
Allergic/Immunologic Contact dermatitis 
 
Systemic lupus erythematosis 
Propolis, garlic, echinacea, or 
melaleuca oil 
Alfalfa 
 
Endocrinologic Gynecomastia, vaginal bleed-
ing 
Goiters, hyperthyroidism and 
hypothyroidism 
Inhibition of iodine uptake 
Hypoglycemia 
Ginseng 
 
Kelp 
 
Garlic 
Atractylodes, scrofularia, 
lycium, or burdock 
Contains estrogen 
 
Contains iodine 
Renal Diuresis 
 
Hypertension, sodium and 
water retention, or hypokalemia 
Burdock, astragalus, peony, or 
dandelion 
Licorice 
 
 
Glycyrrhiza glabra, Glycyrrhiza 
radix can have same effects 
and is found in 74 % of Chi-
nese herbal teas 
Cardiovascular Hypotension 
 
Hypertension 
Hypertension, coronary spasm, 
palpitations, or tachycardia 
Astragalus, codonopsis, 
prunella, scrofularia, or salvia 
Ginseng 
Ephedra 
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5 AIMS OF THE THESIS 
The goal of this thesis was to shed light on the mechanisms of hepatotoxicity of the phyto-
medicines kava kava and cimicifuga racemosa. 
Herbal medicines have been increasingly consumed over the last two decades. People 
using them were appealed by the idea that they have self-control over their medication and by 
the thought of taking safe medicines. A lot of herbal products have been used for all sorts of 
ailments. But over the years growing evidence for adverse effects outcropped and cases of 
toxicity were reported. This was also the case for the Oceanian plant kava kava, which was 
used for its anxiolytic effect. Kava was suspected to be related to liver toxicity with different 
pictures of liver damage. 
For this reason, in a first project (chapter 6), we aimed to elucidate whether kava is really 
hepatotoxic and if so, by which mechanism. So far, no detailed investigations of the mecha-
nisms possibly leading to hepatotoxicity on cell organelle level have been conducted. For this 
purpose, the hepatocarcinoma cell line HepG2 was used as an in vitro model for studying 
hepatotoxicity. During this work, the focus was put on the determination of apoptosis and 
necrosis and on the function of mitochondria. 
In a further project (chapter 7), two methods assessing cell death (i.e. apoptosis and 
necrosis) were compared: the annexin V / propidium iodide stain and the GFP-method. The 
GFP-method was recently described by Strebel et al. [57] and Steff et al. [58] and is based on 
the phenomenon that intracellular GFP decreases its fluorescence when apoptosis and/or 
necrosis occur. The aims were not only the comparison of the two methods but also the 
characterization and establishment of the GFP-method in liver cell lines. For this purpose 
HepG2 cells and the hepatoblastoma cell line HUH6 were used as model for hepatic cells and 
kava extracts as test compounds which can trigger a toxic response. 
The third project (chapter 8) focused again on the hepatotoxicity of a medicinal herb, 
namely on cimicifuga racemosa. Cimicifuga was so far not related to any relevant, and in the 
narrower sense hepato-, toxicity. However, this herb is often used by women for menopausal 
complaints and a detailed assessment of adverse events has not been performed until now. 
Recently, Prof. Udo Spornitz from the Anatomic Institute of the University of Basel found liver 
steatosis in rats after feeding of high doses of cimicifuga extract. This interesting result led us to 
further evaluate the hepatotoxicity of this herb on cellular level. 
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6.1 Abstract 
Kava is used since ages in Polynesian ceremonials, social occasions or as a medicine. Some 
years ago, kava became popular also in Western countries. It was thought to be a safe drug, 
but lately, several cases of liver toxicity have been published and kava was subsequently 
banned from the market in many countries. Since not much is known about the mechanisms of 
hepatotoxicity of kava, we compared three different kava extracts (a methanolic and an ace-
tonic root and a methanolic leaf extract) with respect to their toxic potential on HepG2 cells. It 
was found that all three extracts showed cytotoxicity starting from about 75 µg/mL on. The mito-
chondrial membrane potential was decreased and the respiratory chain inhibited and uncou-
pled (root extracts) or only uncoupled (leaf extract) at 150 µg/mL, and β-oxidation was inhibited 
by all extracts. Oxidized glutathione (GSSG) was increased, whereas the cellular ATP content 
was maintained, and apoptosis was found at concentrations of 150 µg/mL. These results indi-
cate that the kava extracts are toxic to mitochondria, leading to inhibition of the respiratory 
chain, increased ROS production and to a decrease in the mitochondrial membrane potential. 
This in turn could result in the opening of the permeability transition pore and consequently to 
the rupture of the outer mitochondrial membrane with the release of cytochrome c and apopto-
sis. In predisposed patients, mitochondrial toxicity of kava extract may explain hepatic adverse 
reactions of this drug. 
 
Keywords: kava, piper methysticum, hepatotoxicity, apoptosis, HepG2 
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6.2 Introduction 
Kava kava (Piper methysticum Forster) is a plant originating from Oceania (Polynesia, Melane-
sia and Micronesia). In these regions, kava beverages are consumed for ages at social or 
ceremonial occasions and also as medicines. Medicinal indications are induction of relaxation 
and sleep, but also counteraction of fatigue, congestion in the urinary tract, chronic cystitis, 
asthma, rheumatism, weight reduction, headache, cold, fever, syphilis, gonorrhea and others 
[59]. Traditionally, kava extracts are prepared from kava roots macerated with water or coconut 
milk [60, 61]. 
Some years ago, the medicinal plant kava became popular also in Western countries as a 
herbal alternative to commonly used drugs such as benzodiazepines. Depending on the coun-
try, kava was used also for urinary tract infection, as a general tonic, but also against stress, 
anxiety and nervous disorders [62]. Until recently, apart from a so called kava dermatopathy, 
kava was reputed not to cause severe adverse reactions [63]. Occasionally, yellowing of the 
skin, red eyes, and episodes of allergic reactions were noticed, which were all spontaneously 
reversible on stopping of the medication [59]. 
Lately, however, 82 cases of liver toxicity apparently associated with the use of kava dating 
from 1990 – 2002 were reported from several countries [64]. For twenty of these cases, there 
was obviously no connection to kava intake. In 21 reports, patients were treated concomitantly 
with potentially hepatotoxic drugs. In seven cases, the causality of kava could be doubted con-
siderably, whereas in 31 other cases, the available data were too fragmentary for an assess-
ment. This left three cases, in whom the hepatotoxic effects associated with kava could be 
established as probable [64]. In only one of these cases, kava was ingested according the dos-
age recommendations of the German commission E monograph [64]. Nevertheless, based on 
these findings, kava was banned from the market in the European countries, Canada and 
Australia. It was hypothesized that these cases of liver failure might have an immunological 
origin [64-66]. 
To further evaluate the reasons for the toxicity associated with kava, possible mecha-
nism(s) have been investigated by various authors. Several mechanisms and/or risk factors for 
the toxicity of kavalactones were proposed, including glutathione depletion [67], in vitro forma-
tion of electrophilic metabolites such as quinones [68] and genetic polymorphisms for CYP2D6 
[65, 69]. While kavalactones are the pharmacological principle of kava extracts, it remains 
unclear whether they are also responsible for their toxicity. 
Kavalactones, also called kavapyrones, are the major lipophilic compounds in the kava 
root and have been found to be responsible for the anxiolytic effect of kava [69]. Accordingly, 
kava containing a high amount of kavalactones is generally considered to be of high quality 
[70]. The amount of kavalactones varies with the different parts, the age and the cultivar of the 
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plant [71, 72]. Duve et al. [73] found that the total kavalactone content is typically highest in the 
lateral roots and decreases continuously towards the aerial parts. 
It was also speculated whether other components of kava extracts and/or the extraction 
method could be the cause for kava toxicity. Nerurkar et al. [74] and Dragull et al. [70] have 
investigated the alkaloid pipermethystine and found a stronger toxicity in HepG2 cells than for 
kavalactones, which were not toxic at the same concentrations. Coté et al [75] compared the 
effect of an acetonic, an ethanolic and methanolic root extract with a (traditional) aqueous 
extract on cytochrome P450 enzymes (CYP). The aqueous extract was the least potent inhibi-
tor for the examined CYPs. It can also be imagined that kava toxicity originates from interac-
tions with CYPs, because kavalactones and also kava extracts have been shown to interact 
with and to inhibit several CYPs [76]. 
The aim of this study was to gain further insight into the cellular mechanisms of toxicity of 
kava, as so far no extensive investigations of the mechanism of toxicity have been performed. 
In addition, we wanted to find out whether extracts from different parts of the plant and 
extracted with different solvents display a different toxicity. These investigations were also 
carried out with the idea that in the future modified extracts – prepared with different solvents 
and/or extracts from specific parts of the plant - could be utilized in the treatment of humans. 
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6.3 Materials and methods 
6.3.1 Chemicals 
JC-1 and propidium iodide were from Molecular Probes (Eugene, OR, USA); Z-Val-Ala-Asp-
fluoromethylketone (zVAD-fmk) and Z-Phe-Ala-fluormethylketone (zFA-fmk) were from Enzyme 
Systems Products (Livermore, CA, USA); Alexa Fluor 633 labeled annexin V was a kind gift of 
Dr. Felix Bachmann, Aponetics Ltd. (Witterswil, Switzerland). [1-14C]palmitic acid was obtained 
from Amersham Pharmacia Biotech (Dübendorf, Switzerland). The scintillation cocktail was 
from Perkin Elmer (Boston, MA, USA). All other chemicals were from Sigma (Buchs, Switzer-
land) and of highest quality available when not otherwise stated. 
 
6.3.2 Preparation and analysis of the three kava extracts 
A methanolic and acetonic root, and a methanolic leaf extract deriving from the same cultivar, 
harvested from 3 years old greenhouse kava plants, were produced. Dried leaves and lateral 
roots were pulverized in a laboratory mill and extracted twice, either with methanol or acetone, 
in an ultrasonic bath for 15 minutes. The solvents were evaporated to dryness and the residue 
was diluted in methanol and filtered (regenerated cellulose, 0.45 µm) for HPLC analysis. 
A reversed phase HPLC analysis was carried out on a Spherisorb-5 ODS column (5 µm, 
250 x 4.6 mm; Waters, Milford, MA, USA) using a Jasco HPLC system (Easton, MD, USA) 
equipped with an auto sampler and a diode array detector. The samples were chromato-
graphed with 22 % acetonitril, 18 % methanol and 60 % H3PO4 (85 %) as solvent, at a flow rate 
of 0.8 ml/minute and at 60 °C. The identification a nd quantification of the six kavalactones was 
based on comparing the retention times, UV spectra and peak areas with external standards 
(PhytoLab, Hamburg, Germany). Methysticin, dihydromethysticin, kavain and dihydrokavain 
were detected at 240 nm, demethoxyyangonin and yangonin at 360 nm. Solutions of the dried 
extracts and of kavain were prepared in DMSO. 
 
6.3.3 Cell culture 
The human hepatocarcinoma cell line HepG2 was kindly provided by Dr. Dietrich von 
Schweinitz (Department of Pediatric Surgery, Childrens Hospital, University of Basel). The cell 
line was grown in RPMI 1640 medium (supplemented with GlutaMAXTM-I, 25 mM HEPES, 10 % 
(v/v) heat-inactivated fetal bovine serum and 100 U/mL penicillin/streptomycin; all from Gibco, 
Paisley, UK). Culture conditions were 5 % CO2 and 95 % air atmosphere at 37 °C. Experiments 
were performed when the cells had reached a confluence of about 80 %. 
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6.3.4 Cytotoxicity tests 
The sulforhodamine B (SRB) test was performed according to the protocol of Skehan [77]. For 
the lactate dehydrogenase (LDH) assay, cells were incubated with the extracts in a 96-well 
plate (Becton Dickinson, Franklin Lakes, NJ, USA) for the indicated time period. 200 µL of the 
supernatant were used for the detection of the LDH activity according to the method of Vassault 
[78]. 
To examine cell viability and activity of the mitochondrial electron transport chain, the dye 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] was used [79]. This assay is 
based on the ability of living cells to (reductively) convert the dissolved MTT (yellow) into the 
insoluble formazan (blue). The latter can be measured colorimetrically and is proportional to the 
amount of living cells. For this assay, 50'000 cells/well were incubated in a 96-well plate in the 
presence of kava extracts for 24 h. After washing, 0.5 % MTT was added for 4 h. The reaction 
was stopped with 100 µL sodium dodecyl sulfate 20% and absorption was measured at 550 nm 
(Spektra Max 250, Molecular Devices, Sunnyvale, CA, USA). 
 
6.3.5 Mitochondrial function 
To assay the mitochondrial membrane potential, the JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetra-
ethyl-benzimidazolylcarbocyanine iodide) assay was performed according to the protocol of 
Molecular Probes. After detachment of the cells with 10 mM EDTA, they were filtered through a 
40 µm mesh. 100'000 cells were incubated in the presence of the kava extracts and JC-1 
(7.5 µM). Subsequently, cells were analyzed by flow cytometry (FACSCalibur, Becton 
Dickinson). 
 
6.3.6 Animals 
Male Sprague Dawley rats (Charles River, Les Onins, France) were used for all experiments. 
They were fed ad libitum and hold on a 12-hour dark and light cycle. The study protocol had 
been accepted by the Animal Ethics Committee of the Canton of Basel. 
 
6.3.7 Isolation of rat liver mitochondria 
Rats were anesthetized with carbon dioxide and killed by decapitation. The liver was extirpated, 
rinsed, minced and washed with ice-cold MSM buffer (220 mmol/L mannitol, 70 mmol/L 
sucrose, 5 mmol/L 3-[N-Morpholino]propanesulfonic acid (MOPS), pH 7.4). Mitochondria were 
isolated by differential centrifugation according to the method of Hoppel et al [80]. The mito-
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chondrial protein content was determined using the Biuret method with bovine serum albumin 
as standard [81]. 
 
6.3.8 Oxygen consumption 
Polarographic monitoring of oxygen consumption was carried out in a 1 mL chamber equipped 
with a Clark-type oxygen electrode (Yellow Springs Instruments, Yellow Springs, OH, USA) at 
30 °C as described previously [82]. The oxygen cont ent of respiration buffer equilibrated with 
air was assumed to be 223 nmol O2/mL at 30 °C [83]. The final concentration of the s ubstrate 
L-glutamate was 20 mmol/L. The respiratory control ratio (RCR) was determined as a marker of 
the functional integrity, i.e. the coupling of oxidative phosphorylation of the mitochondria. The 
RCR was calculated according to Estabrook [84] as the ratio between the rate of oxygen 
consumption in the presence of a substrate and added ADP (state 3) and the rate obtained 
after complete conversion of ADP to ATP (state 4). 
After depletion of endogenous substrates by the addition of ADP, the substrate to be tested 
was added to the incubation. Subsequently, state 3 respiration was initiated by adding ADP 
(final concentration 100 µM). The test compounds were added to the mitochondrial incubations 
before the addition of the substrate L-glutamate. Subsequent experiments with the F1F0-
ATPase inhibitor oligomycin (5 µg/mL) were performed to check whether a possible drop in the 
RCR derives from uncoupling or increased intramitochondrial metabolism of ATP. An uncoupler 
is able to dissipate the proton gradient over the inner mitochondrial membrane and thereby to 
reinitiate the electron and oxygen flow even when the mitochondrial ATPase is inhibited. 
 
6.3.9 In vitro mitochondrial β-oxidation 
Beta-oxidation with freshly isolated liver mitochondria was assessed as the formation of 14C-
acid-soluble β-oxidation products from [1-14C]palmitic acid in the presence of the kava extracts. 
Experiments were performed as described previously [85] with the modifications described by 
Spaniol et al [86]. After 5 minutes of preincubation with the kava extracts, the reaction was 
started by adding 100 µL 400 µM [1-14C]palmitic acid (0.925 Bq/100 µL) and the incubations 
were carried out at 30 °C for 15 min with slow shak ing. We have shown previously that the 
reaction is in the linear phase at this time point [86]. The reaction was stopped with 200 µL 
20 % perchloric acid and by placing the tubes on ice. After centrifugation for 5 minutes at 
12000x g, the 14C-acid-soluble products in the supernatant were counted. It has been verified 
under the conditions used that the formation of ketone bodies accounts for at least 80 % of the 
[1-14C]-palmitate oxidized [87]. The formation of [14C]CO2 by isolated liver mitochondria was 
considered as negligible. 
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6.3.10 Determination of intracellular GSH and GSSG content 
In order to assess the redox status of the treated cells and possible formation of reactive 
metabolites, determination of GSG (glutathione) and GSSG (oxidized glutathione) was done as 
follows. HepG2 cells were co-incubated with kava for 2 hours, scrapped from the dish, sus-
pended in 1 mL PCA/BPDS (1 mM bathophenanthrolinedisulfonic acid in 10 % perchloric acid) 
and sonicated for 30 seconds (sonicator from Heat Systems Ultrasonics Inc., Farmingdale, NY, 
USA, setting 4.5) in order to lyse them. After centrifugation, the pellet was used for protein 
determination (BCA protein assay kit Pierce, Rockford, IL, USA) and the supernatant for the 
determination of glutathione using the enzymatic recycling assay of Tietze [88], with the modifi-
cations of Griffith [89]. For the determination of total glutathione, the pH of the supernatant was 
adjusted to pH 6 to 7 by the addition of triethanolamine. For GSSG determination, a derivati-
zation with 2-vinylpyridine was performed prior to the pH adjustment. For the enzymatic 
reaction, NADPH (0.21 mM), DTNB (5,5'-dithiobis(2-nitrobenzoic acid), 0.6 mM), glutathione 
reductase (1 U/mL) and sample or standard, respectively, were mixed. The formation of TNB 
(5-thio-2-nitrobenzoic acid) was monitored at 30 °C using a plate reader at 412  nm during 
2 min. Glutathione was quantified by comparing the slope of the samples with the correspon-
ding standard curve. 
 
6.3.11 Apoptosis / Necrosis 
Discrimination between apoptosis and necrosis was done with an annexin V / propidium iodide 
stain and analysis by flow cytometry (FACSCalibur, Becton Dickinson) as described previously. 
HepG2 cells were incubated for 24 hours with the different extracts. After trypsinization and 
centrifugation, cells were resuspended in RPMI 1640 medium (adjusted to 2.5 mM calcium), 
stained with Alexa Fluor 633 labeled annexin V and propidium iodide (final concentration 
1 µg/mL) and analyzed by FACS. Annexin V-positive cells are in early apoptosis, whereas 
annexin V and propidium iodide double positive cells can be in both, late apoptosis or necrosis. 
For the analysis, cells in three regions were added up and the percentage of cells in each 
region was calculated. The three regions were defined as "living cells" (annexin V- and pro-
pidium iodide-double negative), "early apoptotic" (annexin V-positive) and "late apoptotic / nec-
rotic" (annexin V- and propidium iodide-double positive). 
 
6.3.12 ATP determination 
The ATP content of HepG2 cells treated with kava extract was determined with the 
luciferin/luciferase method using an ATP bioluminescence assay kit (Sigma, Buchs, Switzer-
land) as described previously [90]. After treating the cells with the three kava extracts (each 10 
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or 150 µg/mL) for 24 hours, the cells were trypsinized, resuspended in 600 µL water and snap-
frozen in liquid nitrogen. To extract the ATP from the cells, the samples were incubated in 
boiling water for 10 minutes and centrifuged (20'000x g, 5 min, 4 °C) [91]. 100 µL of the 
supernatant were used for the determination of ATP according to the user manual of Sigma. 
The ATP content was calculated by comparison to a standard curve. 
 
6.3.13 Statistical methods 
Data represent mean ± standard error of the mean (SE) of at least n = 3 replicates. Statistical 
analysis of differences between control incubations and incubations with kava extract was per-
formed using analysis of variance (ANOVA) and Dunnett's multiple comparison test as posthoc 
test to localize differences obtained by ANOVA. A p-value < 0.05 was considered to be statisti-
cally significant. 
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6.4 Results 
6.4.1 HPLC analysis of the three kava extracts 
The chromatograms of the extracts showed several peaks which could be identified as 
kavalactones. No clear difference in the total amount of kavalactones was observed in the 
methanolic and the acetonic root extract, respectively. Each of them contained about 80 % 
(w : w) kavalactones (Table 2). However, the leaf extract was clearly distinguishable from the 
root extracts, containing only 24 % kavalactones (Table 2). In the root extracts, the amounts of 
the single kavalactones were distributed more or less equally, meaning that the quantity of 
each kavalactone ranged between 10 – 17 %, with methysticin and kavain being the most 
prevalent. In contrast, the leaf extract contained only about 0.5 – 1 % of each kavalactone, 
apart from dihydromethysticin and dihydrokavain, which were present at about 10 %. Further-
more the leaf extract showed an additional peak which could not be identified and was not 
detectable in the root extract. 
Table 2:  Kavalactone content in % (w : w) of the three kava extracts, analyzed with reversed phase HPLC 
Extract M DHM K DHK Y DMY Total content 
Methanolic root 16.6 12.0 16.2 13.4 13.6 9.8 81.6 
Acetonic root 17.3 12.4 14.4 13.7 13.1 10.6 81.4 
Methanolic leaf 
  0.6 11.3   0.4 10.2   1.1   0.5 24.1 
Abbreviations: M = methysticin, DHM = dihydromethysticin, K = kavain, DHK = dihydrokavain, Y = yangonin, 
DMY = demethoxyyangonin 
 
 
6.4.2 Cytotoxicity 
The cytotoxicity of the three kava extracts was investigated using the hepatocarcinoma cell line 
HepG2. The sulforhodamine B assay (SRB) showed a concentration-dependent toxicity for all 
three kava extracts from a concentration of 50 µg/mL on, when incubated for 24 hours 
(Figure 6). These results were verified with the lactate dehydrogenase (LDH) test, which 
revealed toxicity already after incubation for 1, 3.5 and 5.5 hours at similar concentrations 
(results not shown). 
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Figure 6: Absorption of sulforhodamine B, a marker for cytotoxicity. The lower the absorption, the higher the toxicity 
of the compound. 10'000 cells were incubated for 24 hours with a methanolic root (solid bars), an acetonic 
root (grey bars) or a methanolic leaf (open bars) extract. Proteins of the living cells were stained with 
sulforhodamine B (0.4 %) and the absorption was measured at 540 nm. Results are expressed as mean ± 
SE of 5 determinations. **p < 0.01 vs. control. 
 
After having observed a general toxic effect of the three kava extracts using the SRB and the 
LDH test, further steps were undertaken to clarify the mode of action. As mitochondria are often 
a target of toxicity, the MTT test was performed. This test reflects mainly the mitochondrial 
reductive activity [79]. As shown in Figure 7, reductive activity of HepG2 cells was clearly 
decreased by the two root extracts in a concentration-dependent fashion from 1 µg/mL (ace-
tonic root extract) or 25 µg/mL (methanolic root extract). In comparison, the leaf extract had 
only a moderate effect on reductive capacity of HepG2 cells, but showed also a significant toxi-
city from 10 µg/mL on. 
Kavain, a kavalactone and thus a main component of kava, was tested as well at concen-
trations according to its content in the kava plant and to its content in the kava extracts. At 
concentrations between 0.77 - 7.7 µg/mL, kavain did not show any toxicity on HepG2 cells, 
neither in the LDH, nor in the MTT test (data not shown). 
 
6.4.3 Mitochondrial toxicity of kava extracts 
Since the MTT test suggested a toxic effect of kava extracts on mitochondria, the mitochondrial 
membrane potential was determined in HepG2 cells. Using JC-1 as a marker [92], both root 
extracts dissipated the mitochondrial membrane potential (the methanolic root extract at 100 
µg/mL and the acetonic root extract starting from 50 µg/mL, see Figure 8). In contrast, the leaf 
extract did not affect the mitochondrial membrane potential up to 100 µg/mL. 
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Figure 7: Absorption of MTT, a marker for viability and reductive activity of the cells. The lower the absorption, the 
lower the reductive capacity of the cells. Cells were incubated for 24 hours with a methanolic root (solid 
bars), an acetonic root (grey bars) or a methanolic leaf (open bars) extract, MTT (0.5 %) was added and 
color intensity was measured at 550 nm. Results are expressed as mean ± SE of 10 determinations. 
**p < 0.01 vs. control. 
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Figure 8: Detection of the mitochondrial membrane potential by the dye JC-1. Mapped is the percentage of de-
polarized cells. Cells were incubated for 10 minutes with a methanolic root (solid bars), an acetonic root 
(grey bars) or a methanolic leaf (open bars) extract. Results are expressed as mean ± SE of 
3 determinations. *p < 0.05 vs. control, **p < 0.01 vs. control. 
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Since the function of the respiratory chain is important for the maintenance of the mito-
chondrial membrane potential, oxidative metabolism was tested in the presence of kava 
extracts using isolated rat liver mitochondria. In the presence of 150 µg/mL root extract, state 3 
oxidation rates were significantly inhibited, but not in the presence of the leaf extract at the 
same concentration or in the presence of 7.7 µg/mL kavain. In contrast, neither of the root 
extracts affected state 4 oxidation rates, whereas state 4 showed a significant increase in the 
presence of 150 µg/mL leaf extract (Figure 9). 
In order to investigate uncoupling of oxidative phosphorylation the F1F0-ATPase inhibitor 
oligomycin was added. The latter is able to induce an artificial state 4 also called state 4u. 
Under such conditions, uncouplers are able to increase oxygen consumption, reflected in an 
increase of state 4u. As shown in Figure 9C, both root extracts and also the leaf extract led to a 
significant increase in state 4u oxygen consumption at 150 µg/mL. In contrast, such an 
increase could not be shown in the presence of 7.7 µg/mL kavain. 
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Figure 9: Oxygen consumption (natoms O/mg protein/min) was measured using isolated rat liver mitochondria and 
glutamate as a substrate. The rate of oxygen consumption in the presence of added ADP (state 3, 
Figure 9A) and the rate obtained after complete conversion of ADP to ATP (state 4, Figure 9B) was deter-
mined for the three kava extracts and kavain. In a second experiment the mitochondria were preincubated 
with the F1F0-ATPase inhibitor oligomycin (5 µg/mL) in order to investigate uncoupling of oxidative phos-
phorylation (Figure 9C). MR = methanolic root, AR = acetonic root, ML = methanolic leaf extract. Results 
are expressed as mean ± SE of 3 determinations. *p < 0.05 vs. control, **p < 0.01 vs. control. 
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Besides the respiratory chain, β-oxidation of fatty acids represents another target of mito-
chondrial toxicity. Using freshly isolated rat liver mitochondria, all three extracts showed a 
concentration-dependent inhibition of the activity of mitochondrial β-oxidation as compared to 
the control (0.61366 nmoles/min/mg = 100 %) (Figure 10). For the two root extracts, inhibition 
could be demonstrated starting from a concentration of 50 µg/mL, whereas the leaf extract 
showed toxicity starting at 200 µg/mL. At 200 µg/mL, the extent of inhibition was similar for all 
extracts, with the residual activity ranging from 14.7 % to 35.9 % of the activity of the control 
value. 
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Figure 10: Activity of β-oxidation of palmitic acid after incubation with a methanolic root (solid bars), an acetonic 
root (grey bars) or a methanolic leaf (open bars) extract. Results are expressed as mean ± SE of 
3 determinations. *p < 0.05 vs. control, **p < 0.01 vs. control. 
 
6.4.4 Glutathione determination 
The experiments described so far have shown that kava extracts can inhibit and uncouple the 
respiratory chain. Inhibition of the respiratory chain often leads to the generation of ROS [90]. 
To assess whether ROS production takes place, the redox status was determined by measur-
ing the glutathione content and ratio (GSH/GSSG) of the treated cells. The measured gluta-
thione ratio of the cells treated with kava were in the range of 1.5, whereas the ratio of the 
control was 2.90 (Table 3). Therefore, all kava incubations showed a tendency for lowering the 
GSH/GSSG ratio as compared to the control, suggesting production of reactive metabolites 
such as ROS. However, these differences did not reach statistical significance, with the excep-
tion for the leaf extract (p < 0.05). 
 
Hepatic Toxicity of Kava Leaf and Root Extracts 
 
42 
Table 3:  Glutathione pool of HepG2 cells treated with kava extracts 
 GSH GSSG GSH/GSSG 
 µg GSH/mg protein  
Control 
 12.6 ± 0.70  4.48 ± 0.42  2.90 ± 0.41 
Antimycin A 10 µg/mL 
 8.88 ± 1.69  7.62 ± 2.24  1.23 ± 0.14 * 
MR 10 µg/mL 
 9.82 ± 1.24  5.82 ± 0.70  1.80 ± 0.45 
MR 150 µg/mL 
 7.98 ± 1.29  5.30 ± 1.00  1.73 ± 0.63 
AR 10 µg/mL 
 10.2 ± 1.2  7.49 ± 0.97  1.45 ± 0.32 
AR 150 µg/mL 
 10.6 ± 1.6  6.89 ± 1.17  1.75 ± 0.63 
ML 10 µg/mL 
 11.5 ± 0.8  8.47 ± 1.10 *  1.43 ± 0.29 * 
ML 150 µg/mL 
 8.65 ± 2.42  9.47 ± 0.93 *  0.99 ± 0.39 * 
Antimycin A was used as positive control. GSH = reduced glutathione, GSSG = oxidized glutathione; MR = methano-
lic root, AR = acetonic root, ML = methanolic leaf extract; *p < 0.05 vs. control 
 
 
6.4.5 Discrimination between apoptosis and necrosis by annexin V and 
propidium iodide staining 
Mitochondria play a key role in the mechanisms of apoptotic but also necrotic cell death [6, 15, 
16, 31]. In the view of the toxicity of the kava extracts on this organelle, the kind of cell death, 
namely apoptosis or necrosis, was assessed. Therefore, staining with fluorescence labeled 
annexin V in combination with propidium iodide was performed on HepG2 cells exposed to the 
kava extracts. As shown in Figure 11, both root extracts (Figure 11A and B) and the leaf extract 
(Figure 11C) induced a concentration-dependent increase in the apoptotic and/or necrotic/late 
apoptotic cell population at 150 µg/mL. The specifity of this mechanism was shown by adding 
the pancaspase-inhibitor zVAD-fmk to the incubations, which was able to reduce early and/or 
late apoptosis; this was not the case with the negative control zFA-fmk. The serine protease 
inhibitor Pefablock did not seem to have this effect, since it reduced toxicity only in combination 
with zVAD-fmk. 
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Figure 11: HepG2 cells were separated into the three categories living cells (black bars), early apoptotic cells (grey 
bars) and late apoptotic/necrotic cells (open bars). Distinction between these three groups has been 
done by a combined annexin V / PI stain, analyzed with FACS as described in Methods. Cells have 
been incubated for 24 hours with a methanolic root (Figure 11A), an acetonic root (Figure 11B) or a 
methanolic leaf (Figure 11C) extract. MR = methanolic root, AR = acetonic root, ML = methanolic leaf 
extract. Additionally, 3 hours-preincubations with the pancaspase-inhibitor zVAD, the corresponding 
negative control zFA, and the serine protease inhibitor Pefablock have been performed. Results are 
expressed as mean ± SE of at least 3 determinations. *p < 0.05 vs. control, **p < 0.01 vs. control. 
 
6.4.6 Cellular ATP content 
When stained with annexin V / propidium iodide necrosis or (late) apoptosis could be detected. 
To make a further discrimination between these two modes of cells death, the ATP content of 
treated cells was determined. For the occurrence of apoptosis, normal levels of ATP are 
necessary, whereas low level ATP status is indicative for necrosis. In our experiments, ATP 
levels of the cells treated with the three kava extracts were not decreased compared to the 
control (data not shown). This suggests that cell death in the presence of the kava extracts is 
due to apoptosis and not necrosis. 
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6.5 Discussion 
In the last few years, cases of hepatotoxicity associated with the ingestion of kava kava have 
been published in several countries, including Switzerland, Germany and Canada. In most 
cases, the trigger of the liver toxicity was not clearly identifiable as other medications were 
taken concomitantly or the given data were too fragmentary for an unambiguous assessment. 
Nevertheless, in 3 of the 82 cases, the relationship between intake of kava and hepatotoxicity 
was declared as probable [64] and it could not be ruled out that kava may have led to liver 
damage. For this reason, we examined the toxicity of total kava extracts, prepared from diffe-
rent parts of the plant and extracted with different solvents. 
After having demonstrated toxic effects resulting in cell death using HepG2 cells, additional 
tests were performed with the aim to find out the mechanisms of toxicity. One of these assays 
was the MTT test, a colorimetric method used to assess cytotoxicity and therefore viability of 
cells. Since reduction of MTT is dependent on the activity of the mitochondrial electron trans-
port chain, MTT absorbance is usually interpreted as indicative for mitochondrial damage. To 
determine whether the reduced production of formazan was indeed due to the impairment of 
mitochondrial function by the kava extracts, the mitochondrial membrane potential was mea-
sured using the fluorescent dye JC-1. Depolarization of mitochondria could be demonstrated for 
both root extracts, but not for the leaf extract, a result agreeing well with the MTT test, which 
showed also only a marginal toxicity for the leaf extract. 
The experiments with isolated liver mitochondria definitively demonstrated that kava 
extracts are toxic for mitochondria. The root extracts were shown to act as inhibitors and also 
uncouplers of the respiratory chain and of β-oxidation and the leaf extract as an inhibitor of β-
oxidation and uncoupler of oxidative phosphorylation. In the view that mitochondria are impor-
tant players in cell death induction, apoptosis and necrosis were examined directly. Annexin V 
FACS stains revealed that all kava extracts induced early apoptosis and also late apop-
totic/necrotic cell death. Cell death could be reduced by the pancaspase inhibitor zVAD-fmk, 
therefore clearly demonstrating the involvement of caspases, which are key players of apopto-
sis. It can therefore be speculated that the interaction of the kava extracts with the electron 
transport chain and β-oxidation and uncoupling of oxidative phosphorylation result in a 
decrease of the mitochondrial membrane potential, possibly also via opening of the permea-
bility transition pore [15, 16]. This may lead to the rupture of the outer mitochondrial membrane 
with the release of cytochrome c and other factors and thus, depending on the energetic status 
of the cell, to apoptosis or necrosis [15, 16].  
In order to find out whether ROS and/or other active metabolites are essential in cell death 
associated with kava extracts, we determined the glutathione pool of the cells. An increased 
GSSG and/or a decreased GSH/GSSG ratio would be compatible with reactive metabolites. At 
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least a tendency pointing in this direction could be observed for all three kava extracts, most 
probably indicating increased production of ROS. After an initial insult, the energetic status of 
the cell decides, whether the cell is going into the direction of apoptosis or necrosis. Procas-
pase 9 is activated in an ATP-dependent way to caspase 9, which then activates caspase 3 to 
initiate the final executioner phase of apoptosis [16]. When ATP is depleted, apoptosis is 
blocked, since procaspase 9 cannot be activated. Instead, necrosis is induced by the same 
upstream proapoptotic signals. Our results, showing no reduction of the ATP level, are there-
fore compatible with apoptosis as the principle death mechanism rather than necrosis. 
Our findings suggest that the leaf extract exerts a lower toxicity in some tests as compared 
to the root extracts. This rises the question of whether extracts from other parts of the kava 
plant could be used instead of the root. Public reports indicate that also so-called peelings, 
scrapings, and shavings from the base of the plant are being used for kava trade due to ample 
supply, low cost, and increased demand on the pharmaceutical and herbal supplement mar-
kets. The pharmacologically active kavalactones are present in the underground parts of the 
plants in high quantities, while alkaloids, like pipermethystine, are present in these parts only in 
trace amounts [70]. Instead, alkaloids appear to be concentrated in stem peelings and leaves 
[70, 72, 93]. In traditional kava use, these latter parts of plants are obviously rather avoided for 
preparing kava drinks. Alkaloids are in general considered to be toxic components of plants, 
possibly associated with animal and human hepatotoxicity [94]. Taking into account that above-
ground plant parts tend to contain piperidine alkaloids, Dragull et al advise for caution in using 
these parts for human consumption [70]. This advice is supported by the observation that in 
HepG2 cells, pipermethystine exerted more toxicity as compared to kavalactones [74]. 
Considering the results of our studies, however, showing a higher toxicity of root as compared 
to leaf extracts, mitochondrial toxicity of kava kava appears to be associated with the kavalac-
tone content of the plant parts investigated. 
Finally, it can be estimated whether the used in vitro concentrations of the kava extracts 
correspond to relevant tissue levels in humans. According to the recommendation of the 
German Commission E, the daily consumption of kava should correspond to 60 – 120 mg 
kavalactones. Based on the kavalactone content of our root extracts (i.e. ca. 80 %) and leaf 
extract (i.e. 24 %), 120 mg kavalactones correspond to 150 mg kava root and 500 mg leaf 
extract, respectively. Since kinetic data of kava extracts in humans have not been published, 
our assumptions are based on kinetic data of kavain and its first metabolite OH-kavain [95]. 
After oral ingestion of 3.2 g kavain, maximal plasma concentrations of kavain and OH-kavain 
were in the range of 10 – 40 ng/mL. Assuming a good bioavailability, this corresponded to a 
volume of distribution in the range of 104 L, suggesting an almost exclusive accumulation in 
tissues [95]. After ingestion of 120 mg of kavalactones, tissue concentrations in the range of 
1 - 2 µg/g (corresponding to 2 - 10 µg extract per g of tissue) can be expected, which is in the 
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lower range of where we started to observe mitochondrial toxicity. Since only a minority of per-
sons developed hepatotoxicity after ingestion of kava extracts, an individual predisposition 
appears also to be important, as described for other mitochondrial toxins such as valproate 
[96]. 
The toxicity of kava should not be regarded isolated, however. In comparison with other 
substances used for the same indication, i.e. benzodiazepines and neuroleptic agents, kava 
seems to exert not more adverse effects, even when the worst case scenario regarding hepa-
totoxicity is assumed [97]. 
In conclusion, our data show that kava extracts exert some toxic effects in a model for liver 
toxicity, i.e. HepG2 cells. Disturbance of the mitochondrial metabolism, possibly leading to 
apoptosis, could be seen. Whether these findings can be directly transferred to the human con-
ditions cannot be answered with certainty, as the pharmacokinetic properties of the kava 
extracts are not known exactly. Taking into account the in vitro effects on mitochondria and 
HepG2 cells, it can be speculated that under certain conditions, e.g. mitochondrial diseases, 
individual patients may develop hepatotoxicity due to ingestion of kava extracts. 
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7.1 Abstract 
Background 
Apoptosis and necrosis are important processes in the physiology and pathology of cells. 
Several methods have been used so far to detect and discriminate them, including annexin V / 
propidium iodide (PI) stain. As these methods are quite time and material consuming, other 
investigators have described a method that discriminates the two forms of cell death by 
measuring the decrease of enhanced green fluorescent protein (EGFP) as a marker. So far this 
method was not established on cells of hepatic provenience, therefore the aim of this work was 
to compare the GFP-method to annexin V / PI stain on above mentioned cells. 
Methods 
HepG2 and HUH6 cells have been transduced with a retroviral vector containing EGFP to 
obtain GFP-expressing cell lines. These cells have been incubated with three different kava 
extracts as apoptosis inducing agents. Apoptosis and necrosis have then been detected by 
using annexin V / PI stain and the GFP-method. 
Results 
It was found that also liver cell lines could be used to apply the GFP-method in the detection of 
cell death, as the results from the annexin V / PI stain and the GFP-method corresponded to 
each other. 
Conclusions 
In this report we show the first time that the GFP-method can also be used with cells of hepatic 
provenience to screen for hepatotoxicity. 
 
 
Key words: apoptosis, GFP, annexin V, propidium iodide, kava 
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7.2 Introduction 
Apoptosis and necrosis are important events in the live cycle of a cell. Apoptosis is a tightly 
regulated process, also called programmed cell death, which is important for the regulation of 
the cell homeostasis in the body. Old or damaged cells are discarded by this course of events 
without eliciting an inflammatory response. In contrast to this, necrosis is always a pathological 
event which is associated with inflammation. Necrosis is usually caused by external agents 
(toxins), physical damage or drastic changes of the physiological condition. Apoptosis may also 
be provoked by external substances as well. Apoptosis can represent a strategy against cancer 
cells, sometimes, however, it is an adverse reaction of a drug. Apoptosis is characterized by 
typical morphological changes like chromatin condensation, membrane blebbing, and DNA 
fragmentation, whereas in necrosis, cell swelling develops, finally ending in cell rupture [6]. 
Consequentially, it is also interesting for scientists to study these incidents. Several 
methods have been established and used which detect the characteristic features described 
above, including terminal deoxynucleotidyl transferase (TdT)-mediated end-labeling of DNA 
strand breaks (TUNEL) [98], annexin V / propidium iodide stain [99], and DNA fragmentation 
laddering on agarose gels. All these methods are associated with several handling and wash-
ing steps, leading to time and material-intensive procedures. 
For this reason, Strebel et al. described a novel tool to measure apoptosis and necrosis 
[57]. This method is based on the property of green fluorescent protein (GFP)-containing cells 
to lower or loose their green fluorescence in case of apoptosis or necrosis and will be called 
GFP-method herein. Several human and mouse immune cell lines were found in whom the 
method could be applied, including Jurkat, A20.2J, and PB3c cells. Another research group 
found at the same time similar results using different cell lines [58]. However, the method has 
so far not been applied to liver cell lines. 
GFP is a protein originally stemming from the bioluminescent jellyfish Aequoria victoria. To 
improve its fluorescence many strategies have been followed, including modulation by human 
codon optimization and amino acid mutations [100-102]. In this study we used the enhanced 
GFP (EGFP) which sometimes is also depicted as GFPmut1. EGFP carries two mutations 
(L64F and T65S) which shifts its excitation peak to 488 nm and enhances its fluorescence [102, 
103]. EGFP exhibits a spontaneous, stable fluorescence, which is independent of cofactors or 
substrates and is easy to monitor and quantify. These properties make it an ideal marker for 
several applications [104-107]. 
Lately we investigated the potential toxicity of kava extracts. We have shown that kava 
extracts are toxic on the hepatocarcinoma cell line HepG2 and induce also apoptosis (Lüde et 
al. 2005, unpublished results). Kava kava is a drug, which was widely used in the Western 
countries as an alternative to benzodiazepines for the treatment of anxiety or as mild sedative. 
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But lately, it has been withdrawn from the market as several cases of liver toxicity have been 
reported [64]. 
The aim of this investigation was to compare the GFP-method with the annexin V / PI 
assay and to establish the GFP-method as a procedure to detect apoptosis and necrosis in 
liver cell lines. 
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7.3 Materials and methods 
7.3.1 Materials 
Soluble Fas ligand cellular supernatant (FasL), Alexa Fluor 633 labeled annexin V and Pefa-
block (Pefa), were kind gifts of Dr. Alessandro Strebel, Aponetics Ltd. (Witterswil, Switzerland). 
Z-Val-Ala-Asp-fluoromethylketone (zVAD) and Z-Phe-Ala-fluormethyl-ketone (zFA) were from 
Enzyme Systems Products (Livermore, CA, USA). Propidium iodide (PI) was from Molecular 
Probes (Eugene, OR, USA). The three kava extracts (a methanolic (MR) and an acetonic (AR) 
root , and a methanolic leaf (ML) extract) were kindly provided by Dr. Karin Berger Büter from 
the Institute for Pharmaceutical Biology of the University of Basel. All other chemicals were 
from Sigma (Buchs, Switzerland) and of highest quality available when not otherwise stated. 
 
7.3.2 EGFP-expressing cell lines 
HepG2 and HUH6 cells were retrovirally transfected with an EGFP-expressing vector. The 
vector was constructed based on the vector HLox-CMV-EGFP-IRES-TK [108], which was a 
kind gift of Dr. Didier Trono (Swiss Institute of Technology, Lausanne, Switzerland). The 
thymidine kinase (TK) gene was replaced by a second EGFP sequence. Retrovirus containing 
the newly constructed vector was produced using the cell line 293T (kindly provided by Dr. 
Christian Kalberer, Experimental Hematology, University Hospital Basel) according to the 
method of Salmon et al [108]. Subsequently, the human hepatocarcinoma cell line HepG2 and 
the hepatoblastoma cell line HUH6 (both cell lines kindly provided by Dr. Dietrich von 
Schweinitz, Department of Pediatric Surgery, Children Hospital, University of Basel) were 
stably transduced with virus containing the bicistronic pLOX-EGFP-IRES-EGFP. The resulting 
HepG2-GFP and HUH6-GFP cells were three times batch-sorted on a FACS Vantage SE 
cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) to obtain cells with a high EGFP signal. 
All cells were grown in RPMI 1640 medium (supplemented with GlutaMAXTM-I, 25 mM HEPES, 
10 % (v/v) heat-inactivated fetal bovine serum and 100 U/mL penicillin/streptomycin; all from 
Gibco, Paisley, UK). Culture conditions were 5 % CO2 and 95 % air atmosphere at 37 °C. 
Experiments were performed with cells which were 80 % confluent. 
 
7.3.3 Detection of apoptotic and necrotic cells 
HepG2-GFP and HUH6-GFP cells were incubated in 12-well plates (Becton Dickinson, Franklin 
Lakes, NJ, USA) for 24 hours with kava extracts. As positive control of necrosis the detergent 
NP40 was used and as positive control for induction of apoptosis, soluble FasL cell supernatant 
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[57]. As a negative control for apoptosis the supernatant of cells transfected with the empty 
vector (Sup) was employed. In order to verify apoptotic cell death 3 hour-pre-incubations with 
the pancaspase inhibitor zVAD (final concentration 40 µM) were performed; zFA (final concen-
tration 40 µM) was the according negative control. Additional experiments in HepG2-GFP cells 
with the serine protease inhibitor Pefablock (final concentration 50 µM) were performed to 
assess caspase independent apoptosis. After trypsinization and centrifugation, cells (floating 
and detached cells combined) were resuspended in RPMI 1640 medium (adjusted to 2.5 mM 
calcium) and stained with Alexa Fluor 633 labeled annexin V and propidium iodide (final con-
centration 1 µg/mL). GFP, annexin V, and propidium iodide were detected simultaneously by 
flow cytometry (FACSCalibur, Becton Dickinson) and the results were analyzed using the 
CELLQuest software (Becton Dickinson). Annexin V was acquired on the FL-4, propidium 
iodide on the FL-2 and GFP on FL-1 channel, respectively. Annexin V-positive cells are in early 
apoptosis, whereas annexin V and propidium iodide double positive cells can be in both, late 
apoptosis or necrosis. For the analysis, cells in three regions (R1 – R3) were added up and set 
to 100 %. The percentage of cells in each region was calculated. The three regions were 
defined as "living cells" (annexin V- and propidium iodide-double negative, R1), "early apop-
totic" (annexin V-positive, R2) and "late apoptotic / necrotic" (annexin V- and propidium iodide-
double positive, R3). For the analysis of the GFP-method, cells displayed in the histogram were 
assigned to three regions: High GFP (living cells, R4), intermediate GFP (apoptotic cells, R5) 
and low GFP (necrotic cells, R6). However, during the performance of the experiments it was 
found that the GFP-method could not clearly distinguish between apoptotic and necrotic cell 
death in the used cell lines. For this reason, the two regions R5 and R6 were combined to 
create a new region called "dying cells" R8. Cells in this new region now corresponded to the 
sum of R2 and R3 (= R9) in the annexin V / PI stain. From now on, results were therefore ana-
lyzed comparing these two broader regions. 
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7.4 Results 
The hepatoma cell lines HepG2 and HUH6 were transduced with a retroviral vector in order to 
express EGFP. Subsequently, experiments were carried out in which annexin V / PI staining 
was compared to the GFP-method by the use of flow cytometry. The GFP-method bases on the 
phenomenon that living cells exert a higher GFP signal than apoptotic/necrotic cells [57, 58]. 
After exposure of the GFP-expressing cells to the test substances, annexin V / PI stain was 
performed and subsequently all three fluorescences were analyzed on a FACS. Figure 12 rep-
resents exemplary data of this analysis and demonstrates that a discrimination between living 
and dying cells can be undertaken, whereas necrotic and apoptotic cells can only be clearly 
discriminated with annexin V / PI but not with the GFP-method. 
 
 
Figure 12: Comparison of GFP and annexin V / PI signal in HepG2-GFP cells. (A) corresponds to the control, (B) to 
FasL and (C) to MR 150 µg/mL. A cell pre-selection was done by only further analyzing the cell popula-
tion in R7 (see left dotplot) in order to exclude cell debris and cell aggregates. In the middle histogram, 
EGFP distribution is mapped, R4 being high GFP or living cells, R8 being dying cells (consisting of R5 = 
intermediate GFP or apoptotic cells and R6 = low GFP or necrotic cells). In the right dotplot annexin V / 
PI stain is represented, where R1 corresponds to the living, R2 to the early apoptotic and R3 to late 
apoptotic/necrotic cells. R9 represents dying cells (= R2 + R3), corresponding to R8 in the EGFP-histo-
gram. 
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From the total cell population (depicted in the SSC-FSC-Dotplot) only selected cells were 
further analyzed (R7) to exclude cell debris and cell clusters. These selected cells were 
mapped in the EGFP histogram for analysis of the EGFP fluorescence and in the dotplot for 
annexin V / PI examination. It was found with the GFP-method that FasL as well as methanolic 
root extract elicited cell death with a proportion of about 35 % dying cells (R8); with the annexin 
V / PI stain a similar amount was seen (35 – 40 %, R2 + R3 = R9). In the latter it could also be 
discriminated between early apoptotic (R2) and late apoptotic/necrotic cell death (R3). Whereas 
in the GFP-method this was not possible, as necrotic and apoptotic cell population merged (see 
R5 and R6). 
Experiments with different incubation conditions (e.g. different kava extracts, FasL) were 
performed with HepG2-GFP and HUH6-GFP cells and analyzed as described above. The 
results are summarized in Figures 13 and 14. In Figure 13 the results of the experiments with 
HepG2-GFP cells are depicted. For reasons of clearness, neither data of the living population 
are shown, nor the results of the methanolic leaf extract, which were similar to those of the root 
extracts. Figure 13A represents the amount of dying cells detected with annexin V / PI stain 
and the GFP-method, respectively. It could be shown that the two methods provided almost the 
same results. For all three kava extracts, the methanolic root, the acetonic root and the metha-
nolic leaf extract, the same pattern of changes in living and dying cells was found. At a concen-
tration of 10 µg/mL, kava extracts were not toxic, whereas 150 µg/mL were associated with 
toxicity, which could be inhibited by the pancaspase inhibitor zVAD. The control zFA was not 
able to reduce the toxicity of the extracts, demonstrating the specificity of our findings. Kava 
150 µg/mL + Pefablock had less effect than kava 150 + zVAD, whereas kava 150 µg/mL + 
zVAD + Pefablock corresponded to the incubation kava 150 µg/mL + zVAD. The decrease of 
dying cells in the incubation kava 150 µg/mL + zVAD was not only observed with annexin V / PI 
but also with the GFP-method, suggesting the presence of caspase-dependent apoptosis and 
not only necrosis. 
With annexin V / PI (Figure 13B), a maximum of only about 10 % early apoptotic cells was 
detected, even in the presence of FasL. Nevertheless, incubations with the higher kava con-
centration showed significant increases in early apoptotic cells compared to the control. A clear 
decrease in the population of the living cells (R1) was seen with the different incubation condi-
tions (data not shown), which was reflected in the increasing proportion of late apop-
totic/necrotic cells (R3). With the GFP-method, the dying cell population (R8) revealed clear 
changes with the different incubation conditions, which were also reflected in a corresponding 
decrease of the living cells (R4, data not shown). These changes were almost identical to the 
ones seen with the annexin V / PI stain in the apoptotic/necrotic cells (R9). 
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Figure 13: Comparison of the annexin V / PI- with the GFP-method in HepG2-GFP cells after incubation with diffe-
rent substances (A). Black bars represent dying cells of the annexin V / PI stain (R9), open bars dying 
cells of the GFP-method (R8). Discrimination between apoptotic and necrotic cell death was performed 
with annexin V / PI stain (B). Grey bars represent early apoptotic (R2) and open bars late apop-
totic/necrotic cells (R3). Results are expressed as mean ± SE of at least 3 individual determinations. 
* p < 0.05 vs. control, ** p < 0.01 vs. control; † p < 0.05 vs. FasL, MR 150 µg/mL, AR 150 µg/mL, 
respectively; ‡ p < 0.01 vs. FasL, MR 150 µg/mL, AR 150 µg/mL, respectively. 
 
The comparison of the two methods was repeated with the second hepatic cell line HUH6-GFP 
(Figure 14). These cells showed similar results as obtained with the HepG2-GFP cells and both 
methods revealed comparable percentages of dying cells (Figure 14A). However, when com-
pared to HepG2-GFP cells, the amount of dying cells was much higher, especially for the 
acetonic root and the methanolic leaf extract, which showed a dying population of about 80 – 
100 % with the annexin V / PI stain. Using the GFP-method this amount turned out to be less, 
i.e. about 70 %. This high percentage may be explained by the increased base line level of 
dead cells in HUH6-GFP cell cultures, which could be seen in all populations studied. 
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With the annexin V/PI stain (Figure 14B) even the early apoptotic cell population (R2) 
reached relatively high amounts when incubated with the high kava concentration, i.e. up to 
42 % for the methanolic leaf extract. This is much higher than with the HepG2-GFP cells. 
 
 
Figure 14: Comparison of the annexin V / PI- with the GFP-method in HUH6-GFP cells after incubation with diffe-
rent substances (A). Black bars represent dying cells of the annexin V / PI stain (R9), open bars dying 
cells of the GFP-method (R8). Discrimination between apoptotic and necrotic cell death was performed 
with annexin V / PI stain (B). Solid bars represent living (R1), grey bars early apoptotic (R2), and open 
bars late apoptotic/necrotic cells (R3). Results are expressed as mean ± SE of 3 individual determi-
nations. * p < 0.05 vs. control, ** p < 0.01 vs. control, *** p < 0.001 vs. control; † p < 0.05 vs. FasL, MR 
10 µg/mL, AR 10 µg/mL, ML 10 µg/mL, respectively; ‡ p < 0.01 vs. FasL, MR 10 µg/mL, AR 10 µg/mL, 
ML 10 µg/mL, respectively; $ p < 0.001 vs. MR 10 µg/mL, AR 10 µg/mL, ML 10 µg/mL, respectively. 
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Experiments with freshly isolated hepatocytes from GFP-transgenic mice (C57BL/6-TgN 
(ACTbEGFP)1Osb, obtained from the Jackson Laboratory Bar Harbor, Maine, USA) have also 
been performed. But the results were hardly interpretable, as the GFP expression of the 
hepatocyte preparations were scattered over a very broad range and therefore the shift in the 
fluorescence pattern could not be reliably quantified (data not shown). 
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7.5 Discussion 
Cell death investigations have been conducted using several time and material consuming 
methods, including annexin V / PI stain and DNA fragmentation pattern analysis. In order to 
ease these procedures, Strebel et al [57] and Steff et al [58] described a method where several 
handling steps could be omitted and which was easy to interpret. This method is based on the 
property of GFP to decrease in fluorescence intensity when death-evoking agents act on a cell. 
Such cells were previously prepared by transfection for stable expression of GFP. 
The mechanism by which the GFP fluorescence decreases is still not known. The specula-
tion that GFP would leak out of the cell or be degraded by proteases such as caspases upon 
activation of cell death was ruled out. The GFP-method even worked when cell death was 
mediated by a caspase-independent pathway and the GFP amount in the cell was similar in 
living and dying cells as could be shown by Western blot experiments [58]. Another explanation 
for the decrease of GFP could be the influence of the intracellular pH. It was found that most 
GFP mutants rapidly respond to pH changes in the way that cytosolic acidification leads to 
reduced GFP fluorescence [109]. This makes them an ideal tool to monitor intracellular pH 
[110, 111]. A decrease in pH (around 0.4 U) was indeed observed in cells undergoing the apop-
totic process [112-114]. In addition, it could be evidenced that redox changes influence the 
fluorescence of GFP [115, 116]. Therefore, redox events occurring during apoptosis may also 
contribute to the loss of GFP fluorescence. 
Our experiments were performed with different kava extracts, substances found to be 
cytotoxic in an earlier study (Lüde et al., unpublished results). Their ability to trigger cell death 
was investigated in this study by comparing and using the GFP and the annexin V / PI method. 
It was found that these two methods provided similar results, when comparing the percentage 
of dying cells. With the GFP-method, a clear discrimination between apoptotic and necrotic 
cells, like with the annexin V / PI stain, could not be obtained, however. Using the GFP-method 
the apoptotic and necrotic cell populations merged and the region setting was therefore not 
feasible. A distinction between apoptotic and necrotic cell death, like it could be shown by 
Strebel et al. [57], might be achievable by using other liver cell lines. Therefore, also a HUH6-
GFP cell line was investigated and showed a better discrimination between necrosis and 
apoptosis, which could not be quantified separately, however. 
When comparing toxicity of the kava extracts on HepG2 and HUH6 cells, respectively, it 
could be seen that the toxic effect on HUH6 cells was higher than on HepG2 cells. Obviously, 
HUH6 cells seem to be more susceptible to damage by kava extracts. This might be due to the 
different origin of these cell lines, HepG2 being a hepatocarcinoma and HUH6 a hepato-
blastoma cell line. The exact reason for this difference could only be studied if the mechanisms 
of hepatotoxicity of kava kava were clear, what is not the case so far, however. 
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It was found in HUH6 cells that apoptosis was not provokable by FasL. This may be 
explained by the fact that HUH6 cells have a low expression of Fas receptor [117]. 
As was shown by [57] and [58], the GFP-method could also be used for plate reader appli-
cation. This is advantageous when screening high numbers of substances. Consequently, the 
plate reader method could represent an alternative to the enzyme (lactate dehydrogenase test) 
or staining tests (sulforhodamine B) used for screening of cell viability. However, the GFP 
method itself will not allow to discriminate between apoptotic and necrotic cell populations in 
the plate reader assay, since the mean of the fluorescence of all cells will be measured. 
However, co-incubations of cell death inducing agents with caspase inhibitors, like zVAD, could 
help to specify the mode of cell death in the same incubation. Nevertheless, other apoptosis-
detecting assays should be used in addition, including annexin V / PI stain, when apoptosis is 
desired to be confirmed. Even so, the GFP-method can be used as an easy, reliable method to 
detect cell death, also in liver cell lines. 
With the annexin V / PI method apoptosis was observed (increase of the early apoptotic 
population), but only to a relatively low – although significant – extent. Instead, the late apop-
totic / necrotic population displayed a greater accumulation of cells. Out of this it was specu-
lated that the early apoptotic pool is rather a transient stage where apoptotic cells pass through 
on the way to the late apoptotic / necrotic stage. In case no significant increase in the early 
apoptotic population occurs a rise of the late apoptotic / necrotic cell pool is interpreted to be 
caused by necrotic cells. 
It can be concluded that the GFP-method is an easy, reliable and stable method which is 
ideal to detect cell death, i.e. apoptosis and necrosis. It was shown in this study that this 
method also works with hepatoma cell lines, but without being able to differentiate between 
apoptosis and necrosis. Nevertheless, in combination with caspase inhibitors and/or other 
assays distinguishing between apoptosis and necrosis, the method is usable to screen for 
hepatotoxicity. 
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8.1 Abstract 
Background/Aims: 
Extracts of cimicifuga racemosa became popular in the last years as natural medicines for the 
treatment of menopausal complaints since hormone replacement therapy was found to be 
associated with breast cancer. Several trials studying the efficacy of cimicifuga have been 
performed, but side effects were not investigated profoundly or considered to be mild. This 
study was designed to assess the potential hepatotoxicity of cimicifuga racemosa. 
Methods: 
Cimicifuga racemosa was fed to rats and liver slices were analyzed by electron microscopy. 
Cytotoxicity tests, apoptosis/necrosis investigations, redox status assessment, and mitochon-
drial membrane potential determination were conducted in the hepatocarcinoma cell line 
HepG2 after incubation with cimicifuga extract. Oxygen consumption and β-oxidation were 
assessed using isolated rat liver mitochondria. 
Results: 
Microvesicular steatosis was found in rats fed with cimicifuga extract (1000 mg/kg). Clear cyto-
toxic effects were detected in vitro from 300 µg/mL on. At this concentration, the mitochondrial 
membrane potential was decreased and apoptosis was induced. Further, oxidative phosphory-
lation was uncoupled and β-oxidation was inhibited. 
Conclusions: 
Cimicifuga racemosa exerts toxicity in vivo and in vitro. Although the concentrations associated 
with toxicity were higher than the expected plasma levels in humans, it can not be excluded 
that cimicifuga extracts are hepatotoxic also in humans. 
 
Key words: Cimicifuga racemosa, Actaea racemosa, black cohosh, hepatotoxicity, apoptosis, 
HepG2 
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8.2 Introduction 
Hormone replacement therapy (HRT) is currently the standard treatment of menopausal 
ailment. Association of HRT with breast cancer and the request of many women for natural 
treatment were the reasons why alternative therapies became popular. Especially extracts of 
the plant cimicifuga racemosa are now widely used for this indication. Cimicifuga racemosa, 
also called Actaea racemosa or black cohosh, is a member of the buttercup family (ranuncu-
laceae) and ethanolic or isopropanolic extracts of it are being used. Cimicifuga racemosa is a 
herb native to the Eastern United States and Canada. Traditionally, the rhizome was used by 
North American Indians for joint aches, myalgias, and neuralgias, as well as menopausal com-
plaints, pain during labour, and also rheumatism. Nowadays, it is most commonly used for 
menopausal symptoms and the premenstrual syndrome, in particular dysmenorrhea [118]. 
Data from clinical studies and from spontaneous reporting programs suggest that adverse 
events with cimicifuga racemosa are rare, mild, and reversible. Gastrointestinal upsets and 
rashes are the most common adverse events reported [119]. These findings were confirmed by 
another review of safety of cimicifuga racemosa: Uncontrolled reports, postmarketing surveil-
lance, and human clinical trials of more than 2,800 patients demonstrated a low incidence of 
adverse events (5.4%). Of the reported adverse events, 97% were minor and did not result in 
discontinuation of therapy, and the only severe events were not attributed to cimicifuga treat-
ment [120]. In larger doses, cimicifuga racemosa can cause dizziness, headaches, giddiness, 
nausea, and vomiting [121]. One case report describes a woman who developed a seizure after 
taking a combination of black cohosh, chasteberry, and evening primrose oil, but no clear 
cause-and-effect relationship was documented [122]. Huntley et al [119] found the following 
cases of more severe adverse events, when taking all the surveillance programs into conside-
ration. There was one case of hepatic failure, two or three cases of hepatitis (one case may be 
a duplicate in two databases), and three cases with increased activity of hepatic enzymes (one 
of them is identical with one of the hepatitis cases mentioned above). In addition, also 
cardiovascular events were reported, including two cases of thrombosis, three cases of hyper-
tension, one with circulatory failure, one with bradycardia, and one with palpitations, ventricular 
and supraventricular extrasystoles. Since these programs based on spontaneous reporting, the 
true adverse rate is most probably higher. 
Since the association of hepatotoxicity with cimicifuga appears to be likely, we tried to 
reproduce such findings in an animal model. Indeed, rats treated with 1000 mg/kg cimicifuga 
extract developed microvesicular steatosis, which may be a mechanism of hepatic toxicity also 
in humans. Using HepG2 cells and isolated mitochondria, we subsequently clarified the 
mechanism of this adverse drug reaction. 
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8.3 Material and methods 
8.3.1 Chemicals 
The dry ethanolic cimicifuga extract was obtained from Zeller AG (Romanshorn, Switzerland, 
batch number V2009). Solutions of the extract were made by dissolving the extract in DMSO. 
Caffeic acid and ferulic acid were purchased from Fluka (Buchs, Switzerland) and cimirace-
moside A was from ChromaDex (Santa Ana, CA, USA). JC-1 and propidium iodide were from 
Molecular Probes (Eugene, OR, USA); Z-Val-Ala-Asp-fluoromethylketone (zVAD-fmk) and 
Z-Phe-Ala-fluormethylketone (zFA-fmk) were from Enzyme Systems Products (Livermore, CA, 
USA); Alexa Fluor 633 labeled annexin V was a generous gift of Dr. Felix Bachmann, Aponetics 
Ltd. (Witterswil, Switzerland). [1-14C]palmitic acid was obtained from Amersham Pharmacia 
Biotech (Dübendorf, Switzerland). The scintillation cocktail was from Perkin Elmer (Boston, MA, 
USA). The Cy3TM conjugated anti-sheep IgG was purchased from Jackson Laboratories (West 
Grove, PA, USA). All other chemicals were from Sigma (Buchs, Switzerland) and of highest 
quality available when not otherwise stated. 
 
8.3.2 Liver sections of rats treated with cimicifuga 
Groups of five female Wistar rats were fed each with daily doses of 1, 10, 100, 300 or 1000 mg 
per kg body weight of cimicifuga racemosa extract. The extract was given suspended in 1 mL 
of an aqueous solution of gum arabic by means of esophageal tube (gavage) over a period of 
21 days. After anaesthesia and decapitation animals were perfused for fixation, tissue blocks 
were excised and prepared for microscopy [123]. 
 
8.3.3 Cell culture 
The human hepatocarcinoma cell line HepG2 was kindly provided by Dr. Dietrich von 
Schweinitz (Department of Pediatric Surgery, Children's Hospital, University of Basel). The cell 
line was grown in RPMI 1640 medium (supplemented with GlutaMAXTM-I, 25 mM HEPES, 10 % 
(v/v) heat-inactivated fetal bovine serum and 100 U/mL penicillin/streptomycin; all from Gibco, 
Paisley, UK). Culture conditions were 5% CO2 and 95 % air atmosphere at 37 °C. Experiments 
were performed when the cells had reached a confluence of about 80 %. 
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8.3.4 Cytotoxicity tests 
To examine cell viability and reductive activity, the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay was performed in HepG2 as described previously [124], 
with a washing step included [79]. 
The sulforhodamine B (SRB) test was performed according to the protocol of Skehan [77] 
and the lactate dehydrogenase (LDH) assay was carried out according to the method of 
Vassault [78]. 
 
8.3.5 Isolation of rat liver mitochondria 
Male Sprague Dawley Rats (Charles River, Les Onins, France) were anesthetized with carbon 
dioxide and killed by decapitation. Liver mitochondria were isolated by differential centrifugation 
according to the method of Hoppel et al [80]. The mitochondrial protein content was determined 
using the biuret method with bovine serum albumin as standard [81]. The study protocol had 
been accepted by the Animal Ethics Committee of the Canton of Basel. 
 
8.3.6 In vitro mitochondrial β-oxidation 
Beta-oxidation with freshly isolated liver mitochondria was assessed as the formation of 14C-
acid-soluble β-oxidation products from [1-14C]palmitic acid in the presence of the cimicifuga 
extracts. Experiments were performed as described previously [85] with the modifications 
described by Spaniol et al [86]. 
 
8.3.7 Oxygen consumption 
Polarographic monitoring of oxygen consumption by rat liver mitochondria was carried out in a 
1 mL chamber equipped with a Clark-type oxygen electrode (Yellow Springs Instruments, 
Yellow Springs, OH, USA) at 30 °C as described prev iously [82]. Subsequent experiments with 
the F1F0-ATPase inhibitor oligomycin (5 µg/mL) were performed to check for uncoupling of 
oxidative phosphorylation [90]. 
 
8.3.8 Mitochondrial function 
To check the mitochondrial membrane potential, the dye JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-
tetraethyl-benzimidazolylcarbocyanine iodide) was used according to the protocol of Molecular 
Probes. After incubation with JC-1 cells were analyzed by flow cytometry (FACSCalibur, Becton 
Dickinson, Franklin Lakes, NJ, USA). 
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8.3.9 Determination of intracellular GSH and GSSG content 
In order to assess the redox status of the treated cells and to check for possible formation of 
reactive metabolites, determination of GSH (glutathione) and GSSG (oxidized glutathione) was 
performed using the enzymatic recycling assay of Tietze [88], with the modifications of Griffith 
[89]. 
 
8.3.10 Apoptosis / Necrosis 
Discrimination between apoptosis and necrosis was done with the annexin V / propidium iodide 
stain. HepG2 cells were incubated for 24 hours with the extract as described in the results 
section. After trypsinization and centrifugation, cells were resuspended in RPMI medium 
(adjusted to 2.5 mM calcium), stained with Alexa Fluor 633 labeled annexin V and propidium 
iodide (final concentration 1 µg/mL) and analyzed by FACS (FACSCalibur, Becton Dickinson). 
 
8.3.11 ATP determination 
The ATP content of HepG2 cells treated with cimicifuga extract was determined with the luci-
ferin/luciferase method using the ATP bioluminescence assay kit from Sigma. After treating the 
cells with the cimicifuga extract (each 10 or 500 µg/mL) for 24 hours, the cells were trypsinized, 
resuspended in 600 µL water and snap-frozen in liquid nitrogen. To extract the ATP from the 
cells, the samples were incubated in boiling water for 10 minutes and centrifuged (20'000x g, 
5 min, 4 °C) [91]. 100 µL of the supernatant were used for the determination of ATP according 
to the user manual of Sigma. The ATP content was calculated by comparison to a standard 
curve. 
 
8.3.12 Hoechst staining 
To confirm apoptosis HepG2 cells were incubated with cimicifuga extract for 24 hours, stained 
with 0.1 mM Hoechst 33342 dye and visualized with an inverted fluorescent microscope 
(Olympus IX50, Hamburg, Germany). 
 
8.3.13 Cytochrome c staining 
100'000 HepG2 cells were seeded into a 8-well chamber slide (Nunc Labtek, Naperville, IL, 
USA) and cultured for two days. Subsequently, cells were incubated for 24 hours with cimici-
fuga extracts as described in the result section. The cells were fixed with 4 % paraformalde-
hyde and rinsed three times with blocking buffer (0.05 % saponin and 3 % BSA in PBS). 75 µL 
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of diluted anti-cytochrome c antibody (1 : 300) were added and incubated for 1 hour at 37 °C. 
After rinsing with blocking buffer, 75 µL diluted Cy3 conjugated anti-sheep IgG (1 : 100) were 
added and incubated for another hour at 37 °C. Cell s were washed once with blocking buffer 
and twice with PBS and then analyzed in the inverted fluorescent microscope with the 
AnalySIS^D software (Olympus). 
 
8.3.14 Statistical methods 
Data represent mean ± standard error of the mean (SE) of at least 3 replicates. Statistical 
analysis of differences between control incubations and incubations with cimicifuga extract was 
performed using analysis of variance (ANOVA) and Dunnett's multiple comparison test to 
localize differences obtained by ANOVA. A p-value < 0.05 was considered to be statistically 
significant. 
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8.4 Results 
Animals fed with lower doses of cimicifuga racemosa extract (1 or 10 mg/kg body weight) 
showed slight alterations of their hepatic morphology, like a moderate increase in mitochondrial 
volume and a slight enlargement of the bile canaliculi (data not shown). The animals fed with 
100 or 300 mg cimicifuga extract/kg body weight showed more dramatic changes like mito-
chondrial vacuoles (data not shown) and, finally, the animals fed with 1000 mg/kg body weight 
developed either a general or a rather circumscribed steatosis. Most obvious signs were an 
accumulation of lipid droplets in their hepatocytes (microvesicular steatosis), glycogen deple-
tion and fragmentation of the rough endoplasmic reticulum to a predominantly vesicular type 
(see Figure 15). 
 
 
Figure 15: Semi-thin section of a liver from a rat treated with 1000 mg/kg body weight cimicifuga extract for 21 
days. The majority of the intracellular vesicles are lipid droplets, they are part of a typical steatotic mor-
phology. The sections have been stained with paraphenylene diamine (PPD). 
 
In view of this findings in vitro tests were performed to investigate the mechanism of cimicifuga 
triggered liver steatosis. Since microvesicular steatosis usually reflects mitochondrial damage 
[125], the MTT test was carried out on HepG2 cells to find out whether the cimicifuga extract 
affects reductive capacity of the cells and exerts cytotoxicity. It could be shown that the cimici-
fuga extract displayed a concentration-dependent toxicity, starting from 75 µg/mL (Figure 16). 
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Figure 16: Cytotoxicity and reductive capability of HepG2 cells after incubation with cimicifuga extracts for 24 
hours. In intact cells MTT is metabolically converted to its blue formazan, whose absorption can be 
measured at 550 nm and is represented here. Results are expressed as mean ± SE of 10 determina-
tions. *p < 0.05, **p < 0.01 vs. control. 
 
Cytotoxicity of cimicifuga racemosa could be confirmed with the LDH and the sulforhodamine B 
test. Both showed also a concentration-dependent cytotoxicity, similar to the MTT test (data not 
shown). Specific components of the cimicifuga extract, namely caffeic acid, ferulic acid and 
cimiracemoside A, showed neither in the MTT test nor in the LDH test any toxicity. 
The mitochondrial membrane potential is influenced by many mitochondrial functions, and 
can therefore be used as a test for screening for mitochondrial toxicity. The mitochondrial 
membrane potential was determined in HepG2 cells in the presence of cimicifuga extract using 
JC-1 as a marker. These experiments revealed a decrease in the membrane potential starting 
from 300 µg/mL cimicifuga extract (Figure 17). 
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Figure 17: Percentage of polarized HepG2 cells after 10 min incubation with cimicifuga and the dye JC-1 (final 
concentration 7.5 µM). Results are expressed as mean ± SE of 3 determinations. *p < 0.05 vs. control. 
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In order to find out the reason for the observed decrease in the mitochondrial membrane 
potential, the function of isolated rat liver mitochondria was studied more closely in the pres-
ence of cimicifuga. Determination of β-oxidation revealed that cimicifuga racemosa inhibited 
β-oxidation starting from 10 µg/mL on (Figure 18). The residual activity at a concentration of 
500 µg/mL was only 8.5 %. 
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Figure 18: Activity of the β-oxidation of palmitic acid by isolated rat liver mitochondria after incubation with cimici-
fuga. Results are expressed as mean ± SE of 3 determinations. **p < 0.01 vs. control. 
 
Oxidative phosphorylation is another important metabolic process in mitochondria. To test its 
functioning, oxygen consumption by isolated mitochondria was assessed after incubation with 
cimicifuga extracts. State 3 oxidation rates were not decreased by any concentration of the 
extract (Figure 19A), whereas state 4 oxidation rates were increased with increasing concen-
tration (Figure 19B), suggesting uncoupling of oxidative phosphorylation. The component 
cimiracemoside did not affect state 3 or state 4 oxidation rates (Figure 19A+B). In order to 
investigate uncoupling of oxidative phosphorylation, state 4u was induced by the addition of 
oligomycin, an inhibitor of F1F0-ATPase. Under such conditions, uncouplers are able to 
increase oxygen consumption. As shown in Figure 19C, cimicifuga extract led to a significant 
increase in state 4u oxygen consumption at 500 µg/mL. Such an increase could not be shown 
in the presence of up to 5 µg/mL cimiracemoside. 
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Figure 19: Oxygen consumption by isolated rat liver mitochondria in the presence of L-glutamate (20 mmol/L) as 
substrate and added ADP (state 3; Figure 19A) and after complete conversion of ADP to ATP (state 4; 
Figure 19B). The test compounds were added to the mitochondrial incubations before the addition of the 
substrate L-glutamate. In an additional experiment, oxygen consumption after the addition of the F1F0-
ATPase inhibitor oligomycin and, subsequently, cimicifuga was determined to study uncoupling of oxi-
dative phosphorylation (state 4u; Figure 19C). Results are expressed as mean ± SE of at least 3 deter-
minations. **p < 0.01 vs. control. Oligo = oligomycin 5 µg/ml; Cimi = cimicifuga; DNP = 2',4'-dinitro-
phenol (an uncoupler). 
 
Since an inhibited or uncoupled respiratory chain often goes along with an increased ROS 
production, the redox status of HepG2 cells was assessed by determining their glutathione 
content. However, a raised GSSG level or an increased GSSG/GSH ratio were not found in 
HepG2 cells, suggesting that ROS do not play a significant role in cimicifuga hepatotoxicity 
(data not shown). 
Mitochondrial damage can be associated with both apoptosis and necrosis [90]. Hence, we 
assessed these possibilities with annexin V and propidium iodide staining of HepG2 cells. As 
shown in Figure 20, the cimicifuga extract induced a concentration-dependent increase in 
apoptotic and/or late apoptotic/necrotic cells, starting from 300 µg/mL. The specificity of this 
mechanism was shown by adding the pancaspase-inhibitor zVAD-fmk to the incubations, which 
was able to reduce early apoptosis significantly. 
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Figure 20: Amount of living (black bars), early apoptotic (grey bars), and late apoptotic/necrotic (open bars) cells 
after 24 hour incubation with the test compounds. The total number of cells analyzed (set as 100 %) 
have been proportionally allotted to the three categories "living cells" (annexin V / propidium iodide-
double negative), "early apoptotic" (annexin V-positive) and "late apoptotic/necrotic" cells (annexin V / 
propidium iodide-double positive). Results are expressed as mean ± SE of 3 determinations. *p < 0.05, 
**p < 0.01 vs. control; #p < 0.05 vs. FasL; $p < 0.05 vs. Cimi 500 µg/mL. 
 
To further discriminate the late apoptotic/necrotic cell population, the cellular ATP content was 
determined. For the occurrence of apoptosis, normal levels of ATP are necessary, whereas a 
low level ATP status is indicative for necrosis. In our experiments, the ATP levels of HepG2 
cells treated with the cimicifuga extract were not different from control levels (data not shown), 
suggesting that apoptosis is likely to occur. 
From the results of the annexin V / propidium iodide stain and the ATP measurements, it 
was assumed that apoptosis occurs during incubation with cimicifuga extract. To further confirm 
these results, Hoechst 33342 stains were performed. These stains revealed that, at a concen-
tration of 500 µg/mL, cimicifuga caused apoptosis as judged from the higher occurrence of 
condensed nuclei (Figure 21). 
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Figure 21: Percentage of apoptotic cells after incubation with cimicifuga and soluble FasL (positive control) for 24 
hours and detection with Hoechst 33342 dye. 5 pictures of different areas of each incubation were 
taken, and the total amount of cells as well as the apoptotic cells were counted. Results are expressed 
as mean ± SE of 3 independent determinations. *p < 0.05 vs. control. 
 
Cytochrome c leakage is another marker of apoptosis triggered by mitochondrial damage [90]. 
However, we found in our experiments that cimicifuga 500 µg/mL provoked no leakage of cyto-
chrome c (data not shown). 
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8.5 Discussion 
Although several studies concerning the efficacy of cimicifuga were carried out not much is 
known about the safety of the extracts used. Either it was not looked at the adverse events or 
there was nothing found/reported or only minor complaints were registered in the studies 
conducted. So, reviews regarding the safety of cimicifuga racemosa did come to the conclusion 
that cimicifuga is a safe herbal medicine when used for short time [118-120, 126]. These con-
clusions were based on the clinical findings in case series and randomized or non-randomized 
studies about the efficacy of cimicifuga. In vitro tests looking at hepatotoxicity have not been 
published so far. Since hepatotoxicity has been reported in some patients, we performed in vivo 
and in vitro studies to reproduce such findings in animals and to find out possible mechanisms. 
We found that cimicifuga racemosa, in the concentrations used by us, inhibits the mito-
chondrial β-oxidation to a large extent. A severe inhibition of hepatic β-oxidation in vivo leads to 
an accumulation of fatty acids in hepatocytes. Fatty acids can be converted to triglycerides, 
which will accumulate and form small vesicles, leading to the picture of microvesicular stea-
tosis. This outcome was found in rats fed with high doses of cimicifuga. Microvesicular 
steatosis can be caused by drugs through different mechanisms, such as sequestration of CoA, 
inhibition or inactivation of enzymes involved in hepatic fatty acid metabolism, or modifications 
of mtDNA [127]. Indeed, cimicifuga extract inhibits β-oxidation in isolated mitochondria, offering 
an explanation for the in vivo findings. 
A mode of cell death that is often found after exposure to different stimuli (chemicals, 
drugs, ionizing irradiation, viruses, depletion of growth factors, hormones and cytokines) is 
apoptosis [17]. Apoptosis can be regarded as a physiological process to control the proliferation 
of cells and tissues. On the other hand, apoptosis associated with drugs can lead to organ 
damage [90]. Considering cimicifuga extract, apoptosis was found in human breast carcinoma 
cell lines after incubation with isopropanolic or ethanolic extracts [128]. Our work demonstrates 
that cimicifuga extracts can trigger apoptosis also in hepatocytes, offering a possible explana-
tion for hepatotoxicity of this drug. The concentrations causing 50 % growth inhibition of human 
breast carcinoma cell lines found by Hostanska et al [128] are lower then the ones we found for 
HepG2 cells, however. Our values, obtained using the SRB and MTT test, were in a range of 
200 µg/mL, theirs between 30 and 80 µg/mL. A reason for this difference may be the different 
cell lines used. 
To assess whether the concentrations used are in the range of the blood concentrations 
reached after ingestion of cimicifuga tablets, a rough estimation is made. Assuming that a tablet 
containing 6.5 mg dried ethanolic extract (contained in Climavita®, Permamed, Switzerland) is 
ingested, the whole extract is absorbed and distributed to body water, a plasma concentration 
in the range of 0.2 µg/mL could be expected. This value is much below the cytotoxic concen-
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trations found in our experiments, but hepatic accumulation of toxic substances during long-
term ingestion of cimicifuga cannot be excluded. 
In comparison to humans, higher doses of cimicifuga were used in the rat experiments. For 
a rat weighing 300 g, daily doses of 0.3 – 300 mg were administered, resulting in plasma con-
centrations in the range of 1.5 – 1500 µg/mL (assuming distribution in the body water). In rats 
in vivo, mitochondrial toxicity started to manifest itself at 100 mg/kg (resulting in plasma 
concentrations of about 150 µg/mL), which corresponds quite well with our in vitro findings. The 
dosages used in humans appear to be too low, however, to be associated with hepatic mito-
chondrial toxicity. 
Cimicifuga racemosa is - as all other plants - a multicomponent drug. The main consti-
tuents of cimicifuga racemosa are triterpene glycosides (actein, 27-deoxyactein, cimifugoside, 
cimiracemoside), phenolic acids (isoferulic acid, fukinolic acid), flavonoids, volatile oils, and 
tannins [129]. The components responsible for the pharmacological effect are not known so far. 
Hostanska et al [130] investigated the main classes of components for their effect on apoptosis. 
The two main classes tested were triterpene glycosides and, due to their similarity to synthetic 
estrogenic compounds, the cinnamic acid esters. Both classes tested were found to induce 
apoptosis in human breast cancer cells. It remains unclear, however, whether these sub-
stances are also the cause for the hepatotoxicity observed in our experiments. 
The formation of quinoid metabolites has also been considered to be a cause of toxicity of 
cimicifuga [131]. Although reactive quinoid metabolites are formed by phase I reactions, in vivo 
studies did not confirm the formation of these products. 
In vivo, cimicifuga toxicity could occur when cimicifuga components are metabolized 
through cytochrome P450 or other enzymes, producing reactive metabolites. But so far, only 
very few data have been published concerning the metabolism of cimicifuga ingredients. In one 
investigation, cimicifuga extract was subjected to microsomal metabolism before cytotoxicity 
tests were performed. However, cytotoxicity was not different to incubations without previous 
treatment with microsomes, strongly suggesting that formation of metabolites is not essential 
for cimicifuga toxicity [130]. These findings are in accordance with our studies, showing a good 
agreement between in vivo and in vitro toxicity and no influence on the glutathione pool in 
HepG2 cells. 
In conclusion, cimicifuga extract is hepatotoxic in rats starting at 100 mg/kg body weight. In 
vitro studies show that this toxicity is due to inhibition of mitochondrial β-oxidation and uncoup-
ling of oxidative phosphorylation, which is associated with hepatocellular apoptosis. In humans, 
the dosages used are too low to explain hepatotoxicity entirely by this mechanism, suggesting 
the presence of additional risk factors. 
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9 CONCLUSIONS AND OUTLOOK 
Today, phytomedicinals are very popular and are therefore widely used. From the consumers 
point of view these medicines are a safe, good working and easily accessible alternative to the 
conventional pharmaceuticals with their side effects and other suspicious properties. From the 
view of a scientist, these herbal products would require a second look. The aspect of efficacy 
has after all been investigated to some extent, but partly there is only the traditional knowledge 
from ancestors or from some tribes. As opposed to this, the issue of safety and quality control 
has been neglected to a great deal. Recently, more and more reports of herb-connected 
adverse reactions became public and the concepts of regulatory authorities point into the direc-
tion of gaining more information about phytomedicines as well. For this reason, efforts are 
undertaken to elicit the mechanisms of action of wanted as well as unwanted effects. This is 
surely highly needed if companies want to further market their phytopharmaceuticals in a 
legally regulated environment. This thesis comprises two projects which support these efforts. 
One work comes actually to late, from the manufacturer's point of view, as kava has already 
been withdrawn from the market in many countries. Despite of this, the results could give hints 
about the precise location where the plant or parts of it act on liver cells in a negative fashion. 
These negative effects might be avoided in future developments when taking the above men-
tioned results into account and when advancing the research based upon the here obtained 
findings. This might include testing of different extracts (i.e. using other solvents or extraction 
procedures), single constituents and/or different parts of the plant. It is important to consider 
that the plants used have the same characteristics and that the raw material is of constant 
quality. 
In the case of cimicifuga or also other phytomedicines the same fate as for kava could 
maybe be anticipated by testing the extracts in an early stage. This means, that the herein used 
methods could represent a basis for testing herbal products regarding their hepatotoxic poten-
tial before they reach market. Of course, other methods should also be added, like animal 
experiments, to evaluate concerns about hepatotoxicity. In addition, similar tests should be 
performed to assess the toxicity for other organs, e.g. brain and kidney. Also metabolic investi-
gations like attributes concerning CYPs are of major interest, as the greatest part of xenobiotics 
are metabolized by these enzymes. Interactions leading to potentially toxic levels of any of the 
involved substances could thus be predicted and hence be avoided to some part. These 
assessments have been performed for kava extracts and kavalactones, which is important. For 
cimicifuga racemosa this has not been done so far. Anyway, not much is known about the toxi-
city of cimicifuga. However, in contrast to kava only very few cases of liver toxicity have been 
reported until now. Nevertheless, clarifications regarding cimicifuga's (liver) toxicity are of great 
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interest, as it is a widely used medicine against menopausal ailments. For this reason, assess-
ment of in vitro hepatotoxicity of cimicifuga was done in this work and toxicity was found 
indeed. What this means, when extrapolated to humans is ambiguous, as only few cases of 
toxicity of cimicifuga were assumed in humans, i.e. one case of autoimmune hepatitis, one 
case of acute liver failure, two cases of "hepatitis", and two cases of mild elevation in liver func-
tion enzymes [132]. As no further cases have been published, despite the widespread use of 
cimicifuga products, it is assumed that the herein toxic concentrations are higher than the con-
centrations obtained in vivo and that other factors might contribute to this liver toxicity. These 
factors may also play a role in liver toxicity cases of other plants and consist of genetic pre-
disposition, pre-existing liver or mitochondrial diseases, gender, age, induced or inhibited CYP 
function, and alcohol (see also chapter 4.3). 
That mitochondria may play an important role in the development of toxicity could be 
deduced from the results of the investigations regarding kava kava and cimicifuga racemosa. 
Mitochondria are central elements in the energy metabolism as well as in live and death of 
cells. Interference with these functions may lead to detrimental outcomes like necrosis or 
apoptosis. However, since lately, not only mitochondria are thought to be involved in the deve-
lopment of apoptosis, but also the endoplasmic reticulum (ER). The ER is the place where 
protein synthesis, protein folding and trafficking, cellular response to stress and intracellular 
calcium levels are regulated. Alterations in calcium homeostasis and accumulation of misfolded 
proteins in the ER cause stress, finally leading to apoptosis [133]. Calcium seems to be 
involved in apoptosis in a manner, that release of calcium from the ER and subsequent mito-
chondrial calcium uptake play an important role in the regulation of the release of cytochrome c 
from the mitochondria [134]. These apoptosis-associated calcium fluxes are under the control 
of the Bcl-2 family of proteins, which also regulate cellular pH and ER resident proteins [134, 
135]. So, further examinations of toxicity mechanisms should also focus on this organelle and 
on calcium levels in the different compartments of cells (i.e. ER, mitochondria, cytosol). Maybe 
some herbal extracts could also be used for the treatment of diseases with diminished apopto-
sis rate like cancer or autoimmunity to induce apoptosis and thus leading to the demise of 
redundant and altered cells. For cimicifuga this purpose was already proposed in the context of 
breast cancer [128]. 
In this thesis, hepatoma cell lines (HepG2 and HUH6) have been used to assess the 
hepatotoxic potential of the two plant extracts. Cell lines are an easy to handle model for the 
investigation of toxicological questions. Despite, attention has to be paid when interpreting data 
stemming from experiments with these cell lines, as carcinoma cells have altered characteri-
stics and metabolism compared to normal liver cells. Therefore, it would be more adequate to 
use freshly isolated liver cells. The best model would be human cells, but this is of course not 
feasible for routine assays. Freshly isolated rat or mouse liver cells could be gained more 
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easily, but then the field of human tissue would have been abandoned. Thus, compromises will 
have to be done when performing (routine) toxicity assays. 
Based on the herein gained results one could ask oneself provocatively whether it is not 
too dangerous to apply phytomedicines at all. Either toxicity has been found in vitro or in clinical 
use or herbal products have not been investigated thoroughly enough. This does not lay a very 
trustful basis for the use of botanicals. Despite, one can not lump together all the phytomedi-
cines and ban all the herbs that have been used for ages without clear toxicity. What probably 
needs to be done is to set rules how herbal remedies should be handled in the future. A start 
would be to first clarify the entitlement of the botanical in question to be further used as 
evidence-based medicine, i.e. with controlled studies. When the further marketing is justified 
from the efficacy point of view then measures to evaluate and report the safety of a phytomedi-
cine should be taken. These measures could first consist of a general obligation to perform (in 
vitro) tests to estimate the toxicity of a herbal product. In addition, instruments to monitor the 
occurrence of negative effects should be established and the attention of medical doctors and 
consumers should be drawn to the fact that also phytomedicines are able to elicit side effects in 
a direct or indirect way and that surveillance of liver enzymes could be appropriate. Addition-
ally, products should be standardized to some main component in order to offer a basis for 
dosage recommendations, methods to test for contamination and adulteration but also for con-
firmation of the presence of the herb in question should be defined, and finally compliance with 
the new regulations has to be monitored. 
In summary, it can be concluded that there needs a lot to be done in the field of phyto-
medicines including enhancement of the awareness of potential toxicity and of the research 
concerning herbal drugs. To finally make a balanced assessment of value of any herbal extract, 
evidence of efficacy has to be weighed against information on safety [48]. In the case of kava 
kava, more investigations should be done when a reintroduction into the pharmaceutical market 
is sought. These investigations would have to consist of additional toxicological experiments 
including different extracts and single compounds to denominate the toxic part of kava. Based 
on these findings new products might be developed to put on the market. Concerning cimici-
fuga racemosa, in vitro investigations suggest some toxicity. However, in reality quasi no cases 
of liver toxicity have been reported. For this reason, further experiments will have to be 
performed in order to scrutinize the (hepato)toxic potential and to define situations in which 
cimicifuga might lead to detrimental outcomes. 
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